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A B S T R A C T
Background
Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal
photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment
such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of vascular proliferation, could improve the
vision of people with PDR.
Objectives
To assess the effectiveness and safety of anti-VEGFs for PDR.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 3), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
April 2014), EMBASE (January 1980 to April 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com),
ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 28 April 2014.
Selection criteria
We included randomised controlled trials (RCTs) comparing anti-VEGFs to another active treatment, sham treatment or no treatment
for people with PDR. We also included studies that assessed the combination of anti-VEGFs with other treatments.
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Data collection and analysis
Two review authors independently selected studies for inclusion, extracted data and assessed risk of bias for all included trials. We
calculated the risk ratio (RR) or the mean difference (MD), and 95% confidence intervals (CI).
Main results
We included 18 RCTs with 1005 participants (1131 eyes) of whom 57% were men. The median number of participants per RCT
was 40 (range 15 to 261). The studies took place in Asia (three studies), Europe (two studies), the Middle East (seven studies), North
America (three studies) and South America (three studies). Eight RCTs recruited people eligible for PRP, nine RCTs enrolled people
with diabetes requiring vitrectomy and one RCT recruited people undergoing cataract surgery. The median follow-up was six months
(range one to 12 months). Seven studies were at high risk of bias and the remainder were unclear risk of bias in one or more domains.
Very low quality evidence from one study of 61 people showed that people treated with bevacizumab and PRP were less likely to lose
3 or more lines of visual acuity at 12 months compared with people treated with PRP alone (RR 0.19, 95% CI 0.05 to 0.81). People
treated with anti-VEGF had an increased chance of gaining 3 or more lines of visual acuity but the effect was imprecise and compatible
with no effect or being less likely to gain vision (RR 6.78, 95% CI 0.37 to 125.95). No other study reported these two outcomes. On
average, people treated with anti-VEGF (bevacizumab, pegaptanib or ranibizumab) had better visual acuity at 12 months compared
with people not receiving anti-VEGF (MD -0.07 logMAR, 95% CI -0.12 to -0.02; 5 RCTs, 373 participants, low quality evidence).
There was some evidence to suggest a regression of PDR with smaller leakage on fluorescein angiography but it was difficult to estimate
a pooled result from the two trials reporting this outcome. People receiving anti-VEGF were less likely to have vitreous or pre-retinal
haemorrhage at 12 months (RR 0.32, 95% CI 0.16 to 0.65; 3 RCTs, 342 participants, low quality evidence). No study reported on
fluorescein leakage or quality of life.
All of the nine trials of anti-VEGF before or during vitrectomy investigated bevacizumab; most studies investigated bevacizumab before
vitrectomy, one study investigated bevacizumab during surgery.
People treated with bevacizumab and vitrectomy were less likely to lose 3 or more lines of visual acuity at 12 months compared with
people given vitrectomy alone but the effect was imprecise and compatible with no effect or being more likely to lose vision (RR 0.49,
95% CI 0.08 to 3.14; 3 RCTs, 94 participants, low quality evidence). People treated with bevacizumab were more likely to gain 3 or
more lines of visual acuity (RR 1.62, 95% CI 1.20 to 2.17; 3 RCTs, 94 participants, low quality evidence). On average, people treated
with bevacizumab had better visual acuity at 12 months compared with people not receiving bevacizumab but there was uncertainty in
the estimate (the CIs included 0; i.e. were compatible with no effect, and there was considerable inconsistency between studies; MD -
0.24 logMAR, 95% CI -0.50 to 0.01; 6 RCTs, 335 participants, I2 = 67%; low quality evidence). People receiving bevacizumab were
less likely to have vitreous or pre-retinal haemorrhage at 12 months (RR 0.30, 95% CI 0.18 to 0.52; 7 RCTs, 393 participants, low
quality evidence). No study reported on quality of life.
Reasons for downgrading the quality of the evidence included risk of bias in included studies, imprecision of the estimates, inconsistency
of effect estimates and indirectness (few studies reported at 12 months).
Adverse effects were rarely reported and there was no evidence for any increased risk with anti-VEGF but given the relatively few studies
that reported these, and the low event rate, the power of the analysis to detect any differences was low.
Authors’ conclusions
There was very low or low quality evidence from RCTs for the efficacy and safety of anti-VEGF agents when used to treat PDR over
and above current standard treatments. However, the results suggest that anti-VEGFs can reduce the risk of intraocular bleeding in
people with PDR. Further carefully designed clinical trials should be able to improve this evidence.
P L A I N L A N G U A G E S U M M A R Y
Injections of anti-vascular endothelial growth factor for advanced diabetic retinopathy
Review question
Do injections of anti-vascular endothelial growth factor (anti-VEGF) help people with advanced diabetic retinopathy in terms of vision
and progression of the disease? Is this treatment safe?
Background
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Diabetic retinopathy is a problem of the back of the eye that occurs in people with diabetes. In later stages of the disease, new blood
vessels grow in the back of the eye and cause problems with vision. This advanced form of the disease is known as proliferative diabetic
retinopathy. Anti-VEGF has been developed to block the growth of these new vessels. It has to be injected into the eye.
Search date
We examined research published up to 28 April 2014.
Study characteristics
We found 18 trials. They took place in Asia (three trials), Europe (two trials), the Middle East (seven trials), North America (three
trials) and South America (three trials). A total of 1005 people took part in these trials and 1131 eyes were studied. Eight trials studied
anti-VEGF with another commonly used treatment for diabetic retinopathy (laser), nine studies looked at anti-VEGF at the time of
diabetic eye surgery (vitrectomy) and one study investigated use of anti-VEGF in people with diabetic retinopathy having cataract
surgery. Most studies followed up the participants for six months but some studies followed up for one year.
Study funding sources
One study was industry funded, one study was funded by a mixture of government and industry, and three studies were funded by
government and non-government organisations. The remainder of the studies did not report a funding source.
Key results
In one small study, we found that people treated with anti-VEGF plus laser were less likely to lose some vision compared with people
treated with laser alone but the estimate was imprecise: around 30% of people treated with laser lost some vision compared with 6%
and 24% of people treated with anti-VEGF plus laser.
On average, people treated with anti-VEGF had slightly better vision than people not treated with anti-VEGF. They were also less
likely to have bleeding in the eye. None of the studies reported on quality of life. One study suggested that injection of anti-VEGF was
less painful than having laser treatment.
People treated with anti-VEGF before or during diabetic eye surgery (vitrectomy) were less likely to lose some vision compared with
people treated with surgery alone, but the estimate was uncertain and it could be that anti-VEGF did not make a difference, or increased
the risk of losing vision. On average, people receiving anti-VEGF before or during diabetic eye surgery had slightly better vision than
people not treated with anti-VEGF, but again the estimate was uncertain. They were also less likely to have bleeding in the eye. None
of the studies reported on quality of life.
Side effects were uncommon and there were not enough data to detect a difference between the two groups.
Quality of the evidence
The quality of the evidence was low or very low. We judged some of the included trials to be at risk of bias because of lack of masking of
treatments and problems with follow-up. Some of the findings were based on too small a numbers of participants. Few studies followed
up participants for more than six months.
3Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anti-VEGF with or without laser (panretinal photocoagulation; PRP) compared with PRP alone for proliferative diabetic retinopathy
Patient or population: people with PDR
Settings: hospital
Intervention: anti-VEGF with or without PRP
Comparison: PRP
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
PRP Anti-VEGF with or without
PRP
Loss of ≥ 3 lines of ETDRS
visual acuity
Follow-up: 12 months
300 per 1000 57 per 1000 (15 to 243) RR 0.19 (0.05 to 0.81) 61 (1 study) ⊕©©©
very low1
Gain of ≥ 3 lines of ETDRS
visual acuity
Follow-up: mean 12 months
10 per 1000 68 per 1000 (4 to 1260) RR 6.78 (0.37 to 125.95) 61 (1 study) ⊕⊕©©
very low1
Visual acuity
logMAR
(logMAR scale value of 0 =
6/6 vision, higher score =
worse vision)
Follow-up: 12 months
The mean visual acuity ranged
across control groups from
0.08 to 0.72 logMAR
The mean visual acuity in the
intervention groups was
0.07 logMAR units lower
(0.12 to 0.02 lower)
- 373 (5 studies) ⊕⊕©©
low2
Regression of proliferative
diabetic retinopathy (as mea-
sured by area of fluorescein
leakage)
Follow-up: 12 months
In 1 trial, people who received bevacizumab in addition to PRP had more regression of PDR, as measured by area of fluorescein leakage at 6 months compared
with people who had PRP alone (MD -8.13 mm2, 95% CI -10.94 mm2 to -5.32 mm2, 19 participants). In another trial, people who received ranibizumab in
addition to PRP had more regression of PDR, as measured by change in area of fluorescein leakage between baseline and 12 months compared with people
who had PRP alone, however, the size of the effect was smaller and the CIs were compatible with no effect, or less regression (MD -1.0 mm2, 95% CI -5.3
mm2 to 3.3 mm2, 20 participants)
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Presence of vitreous/pre-
retinal haemorrhage
Follow-up: 12 months
150 per 1000 48 per 1000 (24 to 98) RR 0.32 (95% CI 0.16 to 0.
65)
342 (3 studies) ⊕⊕©©
low3
Quality of life No data reported on quality of life
Adverse effects Adverse effects were reported in 3 studies: 1 study of bevacizumab plus PRP compared with PRP alone and followed up to 3 months (61 participants); 1
study of ranibizumab compared with saline (both groups received PRP if indicated) and followed up to 4 months (261 participants); 1 study of ranibizumab
plus PRP compared with PRP alone and followed up to 12 months (31 participants)
• Neovascular glaucoma: RR 1.09 (95% CI 0.07 to 17.21; 1 RCT, 261 participants)
• Retinal detachment: RR 0.99 (95% CI 0.44 to 2.25; 1 RCT, 261 participants)
• Cataract: RR 0.32 (95% CI 0.01 to 7.63; 1 RCT, 61 participants)
• Raised intraocular pressure: 2 different estimates from 2 trials: RR 0.11 (95% CI 0.01 to 1.92; 1 RCT, 61 participants) and RR 0.92 (95% CI 0.49 to 1.
70; 1 RCT, 261 participants)
• Cerebrovascular accident: RR 3.26 (95% CI 0.13 to 79.34; 2 RCTs, 322 participants)
• Endophthalmitis: RR 0.36 (95% CI 0.01 to 8.82; 1 RCT, 261 participants) - but unusual trial as control group received injection of saline, only case of
endophthalmitis
• Arterial hypertension: RR 0.47 (95% CI 0.12 to 1.76; 1 RCT, 261 participants)
• Pain score: MD -56.1 (95% CI -71.9 to -40.3; 1 RCT, 31 participants) in favour of ranibizumab compared with PRP
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; MD: mean difference; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation; RR: risk ratio;
VEGF: vascular endothelial growth factor.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded for risk of bias (-1) (study at high risk of selective reporting bias) imprecision (-1) (wide CIs) and indirectness (-1) (study reported gain/loss of ≥ 2 lines at 3 months only).
2 Downgraded for risk of bias (-1) (3 studies at high risk of bias in ≥ 1 domains) and downgraded for indirectness (-1) (only 1 of the studies followed up to 12 months)
3 Downgraded for risk of bias (-1) (2 studies at high risk of bias in ≥ 1 domain) and downgraded for indirectness (-1) (no study reported at 12 months)
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B A C K G R O U N D
Description of the condition
Introduction and epidemiology
Diabetic retinopathy (DR) is a vascular disorder involving the
retina that is characterised by increased vascular permeability, reti-
nal ischaemia and oedema, and formation of new vessels (neovas-
cularisation) (Carmeliet 2004). DR produces visual impairment
that can progress to blindness. It is a complication of both types
of diabetes mellitus (DM), type 1 and type 2. DR may develop
before a diagnosis of diabetes is made, such that one in five people
with type 2 DM has retinopathy at the time of diagnosis. More
than 60% of people with type 2 DM and almost all people with
type 1 DM develop DR during the first 20 years of the disease
(ADA 2006).
A person with diabetes has a three-fold increased risk of blindness
compared with the general population (Hayward 2002). In one
study conducted byMoss et al., the incidence of blindness 10 years
after the onset of DM was 1.8% in people with type 1 DM, 4.0%
in people with insulin-treated type 2 DM, and 4.8% in people
with non-insulin treated type 2 DM (Moss 1994). In the same
study, the incidence of visual impairment at 10 years was 9.4%
in people with type 1 DM, 37.2% in people with insulin-treated
type 2 DM, and 23.9% in people with non-insulin treated type
2 DM. In the USA, in 2002, 17% of blindness was attributed to
DR (Resnikoff 2004).
The principal risk factors for developing DR are the duration
of DM and the severity of hyperglycaemia (Davis 1998; Klein
1988; UKPDSG 1998a; Van Leiden 2003). Other risk factors
are age (in type 1 DM) (Klein 1984), hypertension (Klein 1989;
Klein 2002a; UKPDSG 1998b), nephropathy (Mathiesen 1995),
hypercholesterolaemia (Chew 1996; Klein 2002b; Van Leiden
2002), abdominal obesity and high body mass index (Van Leiden
2003), anaemia (Davis 1998), pregnancy (Klein 1990), age at
onset (Kullberg 2002), smoking and ethnicity (Moss 1996).
Presentation and diagnosis
DR is clinically characterised by a progressive loss of visual acuity
(acuteness or clearness of vision). The retinal damage progresses se-
quentially from a mild non-proliferative stage to a severe prolifera-
tive stage. Signs of non-proliferative diabetic retinopathy (NPDR)
include presence of microaneurysms, intraretinal haemorrhages,
hard exudates (lipid deposits), vascular changes (such as beading
and looping or segmentation of the veins), soft exudates or cotton
wool spots (which result from the closure of small retinal arteri-
oles), intraretinal microvascular abnormalities and retinal oedema.
There are two important NPDR clinical classification systems:
the Early Treatment Diabetic Retinopathy (ETDR) study research
group classification (ETDRSRG 1991a; ETDRSRG 1991b; Table
1) and the International Clinical Diabetic Retinopathy Disease
Severity scale (ICDRDS; Wilkinson 2003; Table 2).
Approximately 50% of people with very severe NPDR progress
to proliferative diabetic retinopathy (PDR) within one year
(ETDRSRG 1991c). PDR is characterised by neovascularisation,
which starts in the retina but can grow and affect the vitreous.
These new vessels are prone to bleeding, which results in vitreous
haemorrhage and fibrosis, and may lead to vitreous or retinal de-
tachments.
Description of the intervention
The treatment strategies for DR include 1. laser photocoagulation
(DRSRG 1978; DRSRG 1981a; DRSRG 1981b; ETDRSRG
1985), 2. vitrectomy (DRVSRG 1985), and 3. pharmacotherapy
to prevent both the retinal neovascularisation and the blood flow
abnormalities affecting metabolic pathways. Generally, the drug
is administered by intravitreal injection.
There are several lines of treatment including vascular endothelial
growth factor (VEGF) inhibitors (anti-VEGF). Some anti-VEGFs
are non-selective, such as corticosteroids (Jaffe 2006; Martidis
2002; Nauck 1997), cyclo-oxygenase inhibitors (Sennlaub 2003),
and angiotensin-converting enzyme (ACE) inhibitors (Gilbert
2000).Other anti-VEGFs are selective, such as pegaptanib sodium
(Adamis 2006; Cunningham 2005), and antibodies such as beva-
cizumab (Arevalo 2007; Avery 2006a; Avery 2006b; Chen 2006;
Haritoglou 2006; Mason 2006; Scott 2007; Spaide 2006), and
ranibizumab (Chun 2006), which cause regression of neovascu-
larisation, macular oedema, or both.
How the intervention might work
VEGFs are present in the retinal pigment epithelium, pericytes and
endothelial cells of the retina. VEGFs are released physiologically
when ischaemia occurs and they stimulate the formation of new
blood vessels.Hyperglycaemia induces chronic retinal hypoxia and
leads to the over-expression of VEGFs that stimulate the formation
of neovascularisation (Bussolati 2001), and cause vascular disease
in the retina.
Selective anti-VEGF drugs inhibit only specific VEGF isoforms,
pegaptanib (a modified oligonucleotide) inhibits only the VEGF
165 isoform. Bevacizumab and ranibizumab (amurine humanised
monoclonal antibody fragment) inhibit all isoforms of VEGF-A.
Some studies showed that local intravitreal administration of these
drugs may be useful in macular oedema and neovascularisation
although anti-VEGFs can produce local adverse effects (in 1.27%
of cases) such as endophthalmitis (severe inflammation of the in-
traocular cavities usually caused by infection) (Shima 2008), and
systemic adverse effects (in 1.5% of cases) such as acute elevation
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of systemic blood pressure or cerebrovascular accident (CVA) (Wu
2008).
Why it is important to do this review
Despite the standard of care given for the prevention and treat-
ment of DR, it remains an important cause of vision loss. Due
to this, new lines of treatment, such as with selective anti-VEGF
drugs, are being developed. Some of these anti-VEGFs do not
have authorisation to be used in DR and are prescribed as off-
label or compassionate-use drugs, but the evidence that supports
this practice has not been sufficiently determined. One Cochrane
systematic review has been completed on diabetic macular oedema
(DMO) (Virgili 2012). It is important to do a systematic review
that clarifies the efficacy of the selective anti-VEGFs in PDR. In
addition, we examined the evidence from randomised controlled
trials (RCT) on harms of such therapy.
O B J E C T I V E S
To assess the effectiveness and safety of anti-VEGFs for PDR.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs without any date or language restrictions. We
excluded studies that includedDMOas part of the principal inclu-
sion from the review because this has been assessed in theCochrane
review by Virgili 2012.
Types of participants
We included trials in adults (aged 18 years and over) with pro-
liferative DR. We included participants with DR at baseline but
the criteria to be selected in the studies was not based on having
DMO.
There were two different patient groups with proliferative DR:
people who were eligible for laser photocoagulation and people
eligible for vitrectomy due to retinal haemorrhage.We judged that
these two groups were sufficiently different that it did not make
clinical sense to pool the results of these studies; thus, we have
considered them separately. This was a post hoc decision and was
not planned in our protocol.
Types of interventions
We included studies inwhich selective anti-VEGFswere compared
with another active treatment, sham treatment or no treatment.
We also included studies that assessed the combination of anti-
VEGFs with other treatments, for example, photocoagulation.
Two different comparisons were made: anti-VEGFs compared
with panretinal photocoagulation (PRP) and anti-VEGFs as an
adjunct to vitrectomy compared with vitrectomy alone.
Types of outcome measures
Primary outcomes
Best-corrected visual acuity at 12 months.
We used three measures:
• loss of 3 or more lines of vision on the ETDRS visual acuity
charts;
• gain of 3 or more lines of vision on the ETDRS visual
acuity charts.
This 3-line change is equivalent to a doubling of the visual angle.
For studies that did not use the ETDRS chart, we used the mea-
sure of visual acuity reported that corresponded most closely to a
doubling of the visual angle.
We also considered mean visual acuity:
• corrected visual acuity measured on a continuous scale
(logMAR visual acuity or ETDRS letters).
Secondary outcomes
• Regression of PDR (i.e. regression of neovascularisation to
an inactive stage as defined with fluorescein angiography (absence
of leakage) or clinical examination (fibrotic new vessels and
absence of haemorrhage from new vessels) or any validated DR
staging system, such as ETDRS or ICRDS scale). We measured
regression sustained at least three months after the last injection.
• Presence of microaneurysms.
• Presence of vitreous or pre-retinal haemorrhage.
• Need for laser photocoagulation.
• Need for vitrectomy.
• People with any ocular or systemic adverse outcomes.
• DMO.
• Quality of life measures in any validated scale.
• Adverse effects.
Search methods for identification of studies
Electronic searches
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We searched CENTRAL (which contains the Cochrane Eyes
and Vision Group Trials Register) (2014, Issue 3), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to April 2014), EMBASE (January 1980 to April 2014),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We
did not use any date or language restrictions in the electronic
searches for trials. We last searched the electronic databases on 28
April 2014.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), mRCT (Appendix 4), ClinicalTrials.gov (Appendix 5) and the
ICTRP (Appendix 6).
Searching other resources
We looked for other published systematic reviews in this area as a
source of additional RCTs. We reviewed the reference lists of the
identified clinical trials. When necessary, we contacted study au-
thors to obtain more information regarding their published trials.
Data collection and analysis
Selection of studies
Two authors (MJM, and JAC or CHF or JRE) independently
assessed the eligibility of the studies identified in the search.When
there were disagreements, a third author (AMC) evaluated the
study independently and discussed it with the remainder of the
team.
We graded the eligible studies as included or excluded. We con-
tacted three study authors to clarify secondary publications of the
main clinical trial (Cho 2010; Ernst 2012; Ramos Filho 2011).
Data extraction and management
Twoauthors (MJM, and JACor JRE) collected data independently
on a previously tested standardised form. The collected informa-
tion recorded the risk of bias, characteristics of participants in the
study, characteristics of the intervention and control groups, and
outcome characteristics of each group of participants. Two review
authors (MJM and JRE) entered the data into Review Manager
5.3 (RevMan 2014).
We contacted two authors to obtain information about missing
data (Farahvash 2011; Rizzo 2008).
When visual acuity was measured using the ETDRS chart but
reported in letters rather than logMAR score, we converted to
logMAR score using the following formula: (85-mean letter score)
* 0.02 and for the standard deviation (SD) (letter score * 0.02)
(Ferris 1982).
Assessment of risk of bias in included studies
Two authors (MJM, and JAC or JRE) assessed the risk of bias
of the included studies, specifically examining the randomisa-
tion method (sequence generation and allocation concealment);
whether the intervention was blinded to the participants, inves-
tigators and outcome assessors; incomplete outcome data; selec-
tive outcome reporting and percentage of losses to follow-up. We
also considered whether the number of post-randomisation losses
and exclusions had beenmade explicit. Once this information was
gathered, the authors classified each study into one of the three
levels of risk of bias: low, unclear or high risk of bias. We followed
the criteria specified in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We considered the following effect measures for each study: risk
ratios (RR) for dichotomous variables and mean differences (MD)
for continuous variables. We calculated 95% confidence interval
(CI).
Unit of analysis issues
The unit of analysis was the eye; most studies included one eye per
person. We excluded from the analysis exclusively within-person
studies (trials where the fellow eye was used as a control) (Ernst
2012; Mirshahi 2008; Preti 2014), but we included studies with
a low percentage of participants with fellow eye used as a control
(Ahn 2011; Cho 2010; Di Lauro 2010; Ergur 2009; Sohn 2012).
Dealing with missing data
We contacted study authors to obtain further information. Our
main analysis has been an ’available-case analysis’, analysing data
as provided in the individual studies.
Assessment of heterogeneity
We examined the characteristics of each study to detect clinical
heterogeneity. We conducted an analysis to detect the presence
of heterogeneity. We regarded an I2 statistic between 50% and
75% as substantial heterogeneity and an I2 statistic between 75%
and 100% considerable statistical heterogeneity, and we studied
sources of heterogeneity.When heterogeneity wasmore than 75%,
we did not pool the studies.
8Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of reporting biases
In accordance with Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Sterne 2011), we did not assess
whether the reviewwas subject to publicationbias by using a funnel
plot because the number of clinical trials identified for inclusion
in the meta-analyses was fewer than 10.
Data synthesis
We determined the pooled effect estimate for each outcome
through a meta-analysis of the individual study effect measures
using a random-effects model (DerSimonian 1986), unless there
were three trials or fewer inwhich casewe used afixed-effectmodel.
We performed statistical analysis using Review Manager 5 (
RevMan 2014).
Subgroup analysis and investigation of heterogeneity
We compared the effect of treatment according to type of anti-
VEGF agent, that is, pegaptanib, ranibizumab and bevacizumab.
Sensitivity analysis
We compared random-effects models and fixed-effect models for
those analyses that had three or more trials.
We compared the results of high risk of bias trials (i.e. high risk of
bias in one or more domains) and low risk trials (i.e. not high risk
in any domain) for those analyses that had more than two trials
contributing to the analysis and at least one trial in each high risk/
low risk group.
’Summary of findings’ table
We prepared two ’Summary of findings’ tables, including assess-
ment of the overall quality of the evidence for each outcome using
the GRADE scheme (GRADEpro 2014).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The electronic searches yielded 3400 references (Figure 1). Af-
ter removing duplicates, we screened 2774 records and obtained
the full-text reports of 52 potentially relevant publications per-
taining to 42 studies. We included 18 studies (Ahmadieh 2009;
Ahn 2011; Cheema 2009; Cho 2010; Di Lauro 2010; DRCR.Net
2013; El-Batarny 2008; Ergur 2009; Ernst 2012; Farahvash 2011;
González 2009; Mirshahi 2008; Modarres 2009; Preti 2014;
Ramos Filho 2011; Rizzo 2008; Sohn 2012; Zaman 2013), and
excluded 19 studies (Arimura 2009; Fulda 2010; Genovesi-Ebert
2007; Gonzalez 2006; Hattori 2010; Huang 2009; Ip 2012;
Jiang 2009; Jorge 2006; Lanzagorta-Aresti 2009; López-López
2012; Michaelides 2010; Minnella 2008; Scott 2008; Shin 2009;
Stergiou 2007; Tonello 2008; Yeh 2009; Zhou 2010). We have
included five ongoing studies and will assess the data when results
become available.
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Figure 1. Results from searching for studies for inclusion in the review.
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We contacted authors to obtain additional information (Cho
2010; Ernst 2012; Farahvash 2011; Ramos Filho 2011; Rizzo
2008). Three authors responded to our questions (Ernst 2012;
Farahvash 2011; Ramos Filho 2011).
Included studies
Overall, we included data on 1005 participants from 18 RCTs in
the review. Forty-three per cent of participants were women and
57%were men, with a mean age of 56 years (range 44 to 71 years).
The median number of participants per RCT was 40 (range 15 to
261).
Eight studies evaluated anti-VEGF in people who needed PRP.
In six of these studies, anti-VEGF was combined with PRP and
compared with PRP alone (Cho 2010; DRCR.Net 2013; Ergur
2009; Mirshahi 2008; Preti 2014; Ramos Filho 2011); two stud-
ies compared anti-VEGF alone with PRP (Ernst 2012; González
2009). Five of these studies used bevacizumab (Cho 2010; Ergur
2009; Ernst 2012; Mirshahi 2008; Preti 2014); two studies used
ranibizumab (DRCR.Net 2013; Ramos Filho 2011), and one
study used pegaptanib (González 2009).
Nine studies evaluated anti-VEGF as an adjunct to vitrectomy
(Ahmadieh 2009; Ahn 2011; Di Lauro 2010; El-Batarny 2008;
Farahvash 2011; Modarres 2009; Rizzo 2008; Sohn 2012; Zaman
2013). All nine trials used bevacizumab.
One study evaluated bevacizumab applied during the course
of cataract surgery to prevent progression of proliferative DR
(Cheema 2009).
The primary outcome was visual acuity in five trials (Cho 2010;
Ergur 2009; Ernst 2012; Preti 2014; Sohn 2012), incidence
of vitreous haemorrhage in three trials (Ahmadieh 2009; Ahn
2011; Farahvash 2011), feasibility of the surgery in three trials
(El-Batarny 2008;Modarres 2009;Rizzo 2008), regression of PDR
in two studies (González 2009; Mirshahi 2008), progression of
DR and maculopathy in one trial (Cheema 2009), active neovas-
cularisation in one trial (Ramos Filho 2011), cumulative proba-
bility of vitrectomy in one trial (DRCR.Net 2013), clearing of
vitreous haemorrhage in one trial (Di Lauro 2010), severity of in-
traoperative bleeding in one trial (Farahvash 2011), and changes
in contrast sensitivity in one trial (Preti 2014).
The median follow-up of participants was six months (range 1
(Ahmadieh 2009) to 12 months (El-Batarny 2008; Ernst 2012;
Farahvash 2011)).
Only one trial specified the calculation of the sample size
(DRCR.Net 2013). There was imbalance between groups at base-
line in one trial (Sohn 2012). Participants in the control group
were worse than the experimental group at baseline: two had visu-
ally significant cataract (one participant in each group), two had
worsening ischaemia (control group), one had severe neovascu-
lar glaucoma (control group), and one had vitreous haemorrhage
(control group).
Only five trials reported the sources of funding (DRCR.Net 2013;
González 2009; Preti 2014; Ramos Filho 2011; Sohn 2012). One
studywas industry funded (González 2009), one studywas funded
by a mixture of government and industry (DRCR.Net 2013), and
three studies were funded by government and non-government
organisations (Preti 2014; Ramos Filho 2011; Sohn 2012). The
remaining studies did not report a funding source.
Excluded studies
We excluded 19 clinical trials (Arimura 2009; Fulda 2010;
Genovesi-Ebert 2007; Gonzalez 2006; Hattori 2010; Huang
2009; Ip 2012; Jiang 2009; Jorge 2006; Lanzagorta-Aresti 2009;
López-López 2012; Michaelides 2010; Minnella 2008; Scott
2008; Shin 2009; Stergiou 2007; Tonello 2008; Yeh 2009; Zhou
2010). The Characteristics of excluded studies table shows the rea-
sons for exclusion. Briefly, eight studies were prospective non-ran-
domised clinical trials (Fulda 2010; Genovesi-Ebert 2007; Hattori
2010; Huang 2009; Jorge 2006; López-López 2012; Minnella
2008; Yeh 2009), four studies were retrospective (Arimura 2009;
Jiang 2009; Shin 2009; Stergiou 2007), four trials were in peo-
ple with macular oedema (Gonzalez 2006; Ip 2012; Michaelides
2010; Zhou 2010), one study had methodological issues (Scott
2008), one trial was in non-PDR (Lanzagorta-Aresti 2009), and
one trial was partially randomised (Tonello 2008).
Risk of bias in included studies
Figure 2 and Figure 3 show the risk of bias in included studies.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three studies reported methods of sequence generation that we
considered were low risk of bias with mention of computer-gen-
erated random allocation lists (Ahmadieh 2009; González 2009),
and use of random number tables (Rizzo 2008). The remaining
studies did not report how they generated the allocation in enough
detail to enable us to judge.
Only two studies reported adequate methods of allocation con-
cealment. One study had a central online randomisation system
(DRCR.Net 2013), and one study used sealed opaque envelopes
(Ramos Filho 2011). The remainder of the studies did not report
allocation.
Blinding
Five studies reported blinding of participants, personnel and out-
come assessors, usually by means of a sham injection or procedure
(Ahmadieh 2009; Di Lauro 2010; Mirshahi 2008; Sohn 2012),
but in one study, both interventions were delivered by injection
and these were identified by number only (DRCR.Net 2013).
A further four studies reported blinding outcome assessors only
(Cheema 2009; Farahvash 2011; Modarres 2009; Ramos Filho
2011). We judged three studies to be at high risk of bias for blind-
ing because they were not blinded (open label) and the interven-
tions were different (Ahn 2011; Ernst 2012; González 2009).
Incomplete outcome data
Most studies did not appear to have a problem with incomplete
outcome data but, for some studies, it was not clearly reported (Di
Lauro 2010; Modarres 2009; Preti 2014; Rizzo 2008), and three
studies had relatively high loss to follow-up so we judged them
to be at high risk of attrition bias (Ahmadieh 2009; Ernst 2012;
Ramos Filho 2011).
Selective reporting
For most studies, we considered selective outcome reporting was
not a problem because they reported the main outcomes expected
ormentioned them in themethods section of the paper.We judged
three studies to be at high risk of bias for selective reporting because
the outcomes were reported incompletely (Cho 2010), or differed
to those stated in the protocol (Ernst 2012), or on the trials register
(Preti 2014); for one study, this information was unclear (Rizzo
2008).
Effects of interventions
See: Summary of findings for the main comparison Anti-
VEGF with or without laser (panretinal photocoagulation; PRP)
compared with PRP alone for proliferative diabetic retinopathy;
Summary of findings 2Bevacizumab before or during vitrectomy
compared with vitrectomy alone
Comparison 1: anti-vascular endothelial growth
factor with or without panretinal photocoagulation
versus panretinal photocoagulation alone
1.1 Loss of 3 or more lines of ETDRS visual acuity
One study reported loss of visual acuitymeasured as a dichotomous
outcome (Cho 2010). The study reported a cut-point of loss of 2
or more lines at three months and used intravitreal bevacizumab
as an adjunct to PRP (injected one week before laser treatment)
and compared with PRP alone.
Participants who received anti-VEGF before PRP were less likely
to lose visual acuity compared with participants who did not (RR
0.19, 95% CI 0.05 to 0.81; 61 participants).
1.2 Gain of 3 or more lines of ETDRS visual acuity
One study reported gain of visual acuity measured as a dichoto-
mous outcome (Cho 2010). The study reported a cut-point of
loss of 2 or more lines at three months and used intravitreal be-
vacizumab as an adjunct to PRP (injected one week before laser
treatment) and compared with PRP alone.
People who received anti-VEGF were more likely to gain visual
acuity but the CIs were wide and compatible with no effect (RR
6.78, 95% CI 0.37 to 125.95; 61 participants).
1.3 Mean visual acuity
Five trials contributed to the analyses of mean visual acuity. We
planned to collect data on final visual acuity at follow-up. Two
studies reported change in visual acuity from baseline and we in-
cluded this in the analysis (González 2009; Ramos Filho 2011).
Two of the trials used intravitreal bevacizumab (Cho 2010; Ergur
2009), one trial used intravitreal pegaptanib (González 2009),
and two trials used ranibizumab (DRCR.Net 2013; Ramos Filho
2011). Three trials used bevacizumab as an adjunct to PRP (in-
jected at the same time or up to three weeks before PRP) compared
with PRP alone (Cho 2010; Ergur 2009; Ramos Filho 2011).
One trial compared pegaptanib injected every six weeks for 30
weeks with treatment with PRP (González 2009). One trial com-
pared three injections of ranibizumab at baseline, four and eight
weeks with an injection of saline; both groups also received PRP
(DRCR.Net 2013).
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Mean visual acuity was reported at three months (Cho 2010),
four months (DRCR.Net 2013), six months (Ergur 2009), nine
months (González 2009), and 12 months (Ramos Filho 2011).
Peoplewho received anti-VEGFon average hadbetter visual acuity
at follow-up compared with people who received PRP alone (MD
-0.07 logMAR, 95% CI -0.12 to -0.02; 373 participants; Analysis
1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 Anti-vascular endothelial growth factor (anti-VEGF) versus
photocoagulation, outcome: 1.3 Visual acuity [logMAR].
Overall, there was no evidence for heterogeneity (I2 = 0%) and no
evidence for any difference according to type of anti-VEGF (test
for subgroup differences P value = 0.37).
1.4 Regression of proliferative diabetic retinopathy
(dichotomous outcome)
None of the studies reported regression of PDR (dichotomous
outcome).
1.5 Regression of proliferative diabetic retinopathy (mean
area of fluorescein leakage)
People who received bevacizumab in addition to PRP had more
regression of PDR, as measured by area of fluorescein leakage, at
six months compared with people who had PRP alone (MD -
8.13 mm2, 95% CI -10.94 to -5.32; 19 participants; Analysis 1.2;
Ergur 2009).
People who received ranibizumab in addition to PRP had more
regression of PDR, as measured by change in area of fluorescein
leakage between baseline and 12 months, compared with people
who had PRP alone; however, the size of the effect was smaller and
the CIs were compatible with no effect or less regression (MD -1.0
mm2, 95% CI -5.3 to 3.3; 20 participants; Analysis 1.2; Ramos
Filho 2011).
Overall, there was considerable heterogeneity (I2 = 86%) and we
did not pool the data of the two studies. It was unclear whether
or not the differences between the estimates reflected differences
in the interventions or comparators, length of follow-up or some
other attributes of these studies. Intravitreal bevacizumab (1.25
mg) was injected 20 days before three sessions of PRP and com-
pared with PRP alone (Ergur 2009). Ranibizumab 0.5 mg was
injected 60 minutes before PRP and compared with PRP alone
(Ramos Filho 2011).
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1.6 Presence of microaneurysms
None of the studies reported presence of microaneurysms.
1.7 Presence of vitreous or pre-retinal haemorrhage
Three trials reported on the presence of vitreous or pre-retinal
haemorrhage. One of these trials used intravitreal bevacizumab (
Cho2010), one trial used intravitreal pegaptanib (González 2009),
and one trial used ranibizumab (DRCR.Net 2013). Bevacizumab
was used as an adjunct to PRP (injected at the same time or up to
one week before PRP) and compared with PRP alone (Cho 2010).
Pegaptanibwas injected every sixweeks for 30weeks and compared
with treatment with PRP (González 2009). Three injections of
ranibizumab at baseline, four and eight weeks were compared with
an injection of saline; both groups also received PRP (DRCR.Net
2013).
People who received anti-VEGF were less likely to present with
vitreous or pre-retinal haemorrhage compared with people that
received PRP (overall pooled RR 0.32, 95% CI 0.16 to 0.65; 342
participants; Analysis 1.3).
Overall there was no evidence for heterogeneity (I2 = 0%) and no
evidence of any difference according to type of anti-VEGF (test
for subgroup differences P value = 0.67).
1.8 Need for laser photocoagulation
None of the studies reported need for laser photocoagulation.
1.9 Need for vitrectomy
We only found one relevant trial that reported need for vitrectomy
(DRCR.Net 2013). Eyes with vitreous haemorrhage due to PDR
that received ranibizumab were less likely to need vitrectomy by
four months compared with eyes that received saline but the CIs
were wide and compatible with no effect or increased risk of need
for vitrectomy (RR 0.74, 95% CI 0.40 to 1.36; 261 participants).
1.10 Diabetic macular oedema
One trial reported DMO at six months (Ergur 2009). People who
received bevacizumab were less likely to develop DMO but the
CIs were wide and compatible with no effect or reduced risk of de-
veloping DMO (RR 0.14, 95% CI 0.01 to 2.45; 30 participants).
1.11 Quality of life
No studies reported quality of life.
1.12 Adverse effects
One study of bevacizumab (Cho 2010), and two of ranibizumab
(DRCR.Net 2013; Ramos Filho 2011) reported adverse events.
See Analysis 1.4.
Neovascular glaucoma
One trial reported neovascular glaucoma (DRCR.Net 2013). One
person in each arm of the study developed neovascular glaucoma
(RR 1.09, 95% CI 0.07 to 17.21; 261 participants).
Retinal detachment
One trial reported retinal detachment (DRCR.Net 2013). Sim-
ilar numbers of people developed retinal detachment in the
ranibizumab and saline groups (10/125 with ranibizumab versus
11/136 with saline; RR 0.99, 95% CI 0.44 to 2.25; 261 partici-
pants).
Cataract
One trial reported cataract (Cho 2010). People who received anti-
VEGF were less likely to develop cataract compared with people
who did not receive anti-VEGF, but the CIs were wide and com-
patible with no effect or increased risk of cataract (RR 0.32, 95%
CI 0.01 to 7.63; 61 participants).
Raised intraocular pressure
Two trials reported increase of intraocular pressure (IOP) (322
participants) (DRCR.Net 2013; Cho 2010).
People who received bevacizumab were less likely to have devel-
oped increased IOP at three months compared with people who
did not receive anti-VEGF, but the CIs were wide and compatible
with no effect or increased risk of increased IOP (RR 0.11, 95%
CI 0.01 to 1.92; 61 participants; Cho 2010).
The risk of raised IOP was similar between the eyes that received
ranibizumab and eyes that received saline (RR 0.92, 95% CI 0.49
to 1.70; 261 participants; DRCR.Net 2013).
Cerebrovascular accident
Two trials reported CVA (DRCR.Net 2013; Cho 2010). The two
trials reported only one case of CVA in the anti-VEGF group in
DRCR.Net 2013 (RR 3.26, 95% CI 0.13 to 79.34; 322 partici-
pants).
Endophthalmitis
One trial reported endophthalmitis (DRCR.Net 2013). There was
only one case of endophthalmitis, which was in the saline group
(RR 0.36, 95% CI 0.01 to 8.82; 261 participants).
Arterial hypertension
One trial reported arterial hypertension (DRCR.Net 2013). Peo-
ple who received anti-VEGF were less likely to develop arterial hy-
pertension compared with people who did not receive anti-VEGF,
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but the CIs were wide and compatible with no effect or increased
risk of arterial hypertension (RR 0.47, 95% CI 0.12 to 1.76; 261
participants).
Pain
One trial reported pain, which was measured on a 100-mm visual
analogue scale (Ramos Filho 2011). People receiving ranibizumab
intravitreal injection reported a mean pain score of 4.7 (SD 8.4),
which was much lower than people receiving PRP who reported
a mean pain score of 60.8 (SD 29.2). This gave an MD of -56.1
(95% CI -71.9 to -40.3; 31 participants) in favour of ranibizumab
intravitreal injection.
Comparison 2: anti-vascular endothelial growth factor
with vitrectomy compared with vitrectomy alone
Nine trials investigated the use of anti-VEGF with vitrectomy. All
of these studies used bevacizumab.
Three of these studies used a sham injection in addition to vit-
rectomy in the control group (Ahmadieh 2009; Di Lauro 2010;
Sohn 2012), in the other six trials the control intervention was
vitrectomy alone.
2.1 Loss of 3 or more lines of ETDRS visual acuity
Three studies reported loss of visual acuity measured as a dichoto-
mous outcome. One of the studies used the cut-point loss of 3
or more lines (Sohn 2012); but the other two studies reported a
“deterioration”, which was not defined (El-Batarny 2008; Zaman
2013). All studies used intravitreal bevacizumab as an adjunct to
vitrectomy (injected three to seven days before) and compared it
with vitrectomy alone or vitrectomy plus sham injection.
People receiving bevacizumab before vitrectomy were less likely to
lose vision, but the CIs were wide and compatible with no effect
or increased risk of losing vision (RR 0.49, 95% CI 0.08 to 3.14;
94 participants; I2 = 0%) (Analysis 2.1).
2.2 Gain of 3 or more lines of ETDRS visual acuity
Three studies reported gain of visual acuity measured as a dichoto-
mous outcome. One of the studies used the cut-point gain of 3
or more lines (Sohn 2012); but the other two studies reported
“improvement”, which was not defined (El-Batarny 2008; Zaman
2013). All studies used intravitreal bevacizumab as an adjunct to
vitrectomy (injected three to seven days before) and compared it
with vitrectomy alone or vitrectomy plus sham injection.
People who received bevacizumab before vitrectomy were more
likely to gain visual acuity compared with people that received
vitrectomy alone (RR 1.62, 95% CI 1.20 to 2.17; 94 participants;
Analysis 2.2). There was inconsistency in the results of the indi-
vidual trials (I2 = 73%) with the RR varying from 1.08 to 3.0,
but as all effects were in the same direction we presented a pooled
estimate.
2.3 Mean visual acuity
Six trials reported mean visual acuity (Ahmadieh 2009; Ahn 2011;
Di Lauro 2010; El-Batarny 2008; Modarres 2009; Sohn 2012).
On average, people receiving bevacizumab before or during vitrec-
tomy had better vision at follow-up (between 2 and 3 lines better),
but the CIs were wide and compatible with no effect of treatment
(MD -0.24 logMAR, 95% CI -0.50 to 0.01; 335 participants; 6
studies; Analysis 2.3; Figure 5).
Figure 5. Forest plot of comparison: 2 Anti-vascular endothelial growth factor (anti-VEGF) plus surgery
versus surgery alone or surgery plus sham or placebo, outcome: 2.3 Visual acuity [logMAR].
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Overall there was substantial heterogeneity (I2 = 67%) but most
of the studies found in favour of bevacizumab.
2.4 Regression of proliferative diabetic retinopathy
None of the studies reported regression of PDR.
2.5 Regression of proliferative diabetic retinopathy (mean
area of fluorescein leakage)
None of the studies reported regression of PDR (mean area of
fluorescein leakage).
2.6 Presence of microaneurysms
None of the studies reported presence of microaneurysms.
2.7 Presence of vitreous or pre-retinal haemorrhage
Seven trials reported presence of vitreous or pre-retinal haemor-
rhage (Ahmadieh 2009; Ahn 2011; Di Lauro 2010; El-Batarny
2008; Modarres 2009; Rizzo 2008; Zaman 2013). All trials used
intravitreal bevacizumab as an adjunct to vitrectomy (injected pe-
rioperatively or up to three weeks before, or both) and compared
it with vitrectomy alone or vitrectomy plus sham injection.
People who received bevacizumab before or during vitrectomy
were less likely to have vitreous or pre-retinal haemorrhage at fol-
low-up compared with people who had vitrectomy alone (overall
pooled RR 0.30, 95% CI 0.18 to 0.52; 393 participants; Analysis
2.4). Overall there was some heterogeneity (I2 = 47%).
2.8 Need for laser photocoagulation
None of the studies reported need for laser photocoagulation.
2.9 Need for vitrectomy
Need for vitrectomy was not relevant, as participants had vitrec-
tomy.
2.10 Diabetic macular oedema
None of the studies reported DMO.
2.11 Quality of life
None of the studies reported quality of life.
2.13 Adverse effects
See Analysis 2.5.
Neovascular glaucoma
One trial reported neovascular glaucoma (Ahn 2011). People who
received anti-VEGF were more likely to develop neovascular glau-
coma compared with people who did not receive anti-VEGF, but
the CIs were wide and compatible with no effect or reduced risk
of neovascular glaucoma (RR 2.33, 95% CI 0.28 to 19.17; 107
participants).
Retinal detachment
Three trials reported retinal detachment (Ahn 2011; Farahvash
2011; Modarres 2009). People who received anti-VEGF were less
likely to develop retinal detachment compared with people who
did not receive anti-VEGF, but the CIs were wide and compatible
with no effect or reduced risk of retinal detachment (RR 0.56,
95% CI 0.11 to 2.86; 182 participants; I2 = 0%).
Cataract
Two trials reported cataract (Ahn 2011; El-Batarny 2008). Peo-
ple who received anti-VEGF were less likely to develop cataract
compared with people who did not receive anti-VEGF, but the
CIs were wide and compatible with no effect or increased risk of
cataract (RR 0.68, 95% CI 0.38 to 1.23; 137 participants; I2 =
0%).
Raised intraocular pressure
One trial reported IOP (Ahmadieh 2009). People who received
anti-VEGF were less likely to develop increased IOP compared
with people who did not receive anti-VEGF, but the CIs were wide
and compatible with no effect or increased risk of increased IOP
(RR 0.31, 95% CI 0.01 to 7.47; 68 participants).
Myocardial infarction
Two trials reported myocardial infarction (MI) (Ahmadieh 2009;
Ahn 2011). There were no events in these trials (175 participants).
Cerebrovascular accident
Two trials reportedCVA (Ahmadieh 2009; Ahn2011). There were
no events (175 participants).
Endophthalmitis
None of the studies reported endophthalmitis.
Arterial hypertension
None of the studies reported arterial hypertension.
Pain
None of the studies reported pain.
Comparison 3: anti-vascular endothelial growth
factor with cataract surgery compared with cataract
surgery alone
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Only one trial considered the use of anti-VEGF (bevacizumab) for
PDR at the time of cataract surgery in 88 eyes with DR (Cheema
2009).
At six months after surgery, there was little difference in visual
acuity. The mean logMAR acuity in the bevacizumab group was
0.57 (SD 0.47) compared with a mean visual acuity in the non-
bevacizumab group of 0.56 (SD 0.48) (MD 0.01, 95% CI -0.22
to 0.24). Twenty of 35 people in the bevacizumab group required
further laser treatment compared with 16/33 people of the non-
bevacizumab group (RR 1.18, 95% CI 0.75 to 1.86).
None of the other outcomes was reported.
Sensitivity analysis: random-effects models versus
fixed-effect models
Choice of model did not affect the conclusions with the exception
of analysis 2.3 (mean visual acuity in trials of bevacizumab with
vitrectomy). The 95% CIs of the pooled effect estimate from the
fixed-effect model did not include zero (null value).
Analysis Measure of effect in random-effects models (95% CI) Measure of effect in fixed-effect models
Analysis 1.1 MD -0.07 logMAR (-0.12 to -0.02) MD -0.07 logMAR (-0.12 to -0.02)
Analysis 2.3 MD -0.24 logMAR (-0.50 to 0.01) MD -0.19 logMAR (-0.32 to -0.06)
Analysis 2.4 RR 0.30 (0.18 to 0.52) RR 0.32 (0.24 to 0.45)
CI: confidence intervals; MD: mean difference; RR: risk ratio.
Sensitivity analysis: low risk of bias versus high risk of
bias
For Analysis 1.1 and Analysis 2.3 (mean visual acuity) there was
little difference between the estimates according to risk of bias in
studies. For Analysis 1.3, it was difficult to interpret, as there was
only one low risk of bias trial and there may be other differences
between this study and the other studies. For Analysis 2.4, there
was a difference between the low risk of bias and high risk of bias
trials but it was not in the anticipated direction (i.e. the low risk of
bias trials appeared to demonstrate a larger effect). However, with
only two RCTs in the high risk of bias group, this result must be
interpreted cautiously.
Analysis Measure of effect in studies at low or unclear risk of bias
in all domains (95% CI)
Measure of effect in studies at high risk of bias in ≥ 1
domains (95% CI)
Analysis 1.1 MD -0.10 logMAR (-0.24 to 0.05); 2 RCTs MD -0.06 logMAR (-0.12 to -0.01); 3 RCTs
Analysis 1.3 RR 0.38 (0.18 to 0.81); 1 RCT RR 0.14 (0.02 to 1.08); 2 RCTs
Analysis 2.3 MD -0.29 logMAR (-0.47 to -0.11); 4 RCTs MD -0.20 logMAR (-0.87 to 0.48); 2 RCTs
Analysis 2.4 RR 0.20 (0.10 to 0.37); 5 RCTs RR 0.46 (0.25 to 0.87); 2 RCTs
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CI: confidence intervals; MD: mean difference; RCT: randomised
controlled trial; RR: risk ratio.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Bevacizumab before or during vitrectomy compared with vitrectomy alone
Patient or population: people undergoing vitrectomy for PDR
Settings: hospital
Intervention: bevacizumab before or during vitrectomy
Comparison: vitrectomy alone or vitrectomy with sham injection
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Surgery Anti-VEGF plus surgery
Loss of ≥ 3 lines of ETDRS
visual acuity
Follow-up: 12 months
60 per 1000 29 per 1000
(5 to 188)
RR 0.49
(0.08 to 3.14)
94
(3 studies)
⊕⊕©©
low1
Gain of ≥ 3 lines of ETDRS
visual acuity
Follow-up: 12 months
500 per 1000 810 per 1000
(600 to 1000)
RR 1.62
(1.2 to 2.17)
94
(3 studies)
⊕⊕©©
low 1
Visual acuity
logMAR
(logMAR scale value of 0 =
6/6 vision, higher score =
worse vision)
Follow-up: 12 months
The mean visual acuity ranged
across control groups from
0.51 to 1.46 logMAR units
The mean visual acuity in the
intervention groups was
0.24 logMAR units lower
(0.50 lower to 0.01 higher)
- 335
(6 studies)
⊕⊕©©
low3
Regression of PDR (as mea-
sured by area of fluorescein
leakage)
Follow-up: 12 months
No data reported on regression of PDR
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Presence of vitreous/pre-
retinal haemorrhage
Follow-up: 12 months
500 per 1000 150 per 1000 (90 to 260) RR 0.30 (0.18 to 0.52) 393 (7 studies) ⊕⊕©©
low4
Quality of life No data reported on quality of life
Adverse effects Neovascular glaucoma: RR 2.33 (95% CI 0.28 to 19.17; 1 RCT, 368 participants)
Retinal detachment: RR 0.56 (95% CI 0.11 to 2.86; 3 RCTs, 182 participants)
Cataract: RR 0.68 (95% CI 0.38 to 1.23; 2 RCTs, 137 participants)
Raised intraocular pressure: RR 0.31 (95% CI 0.01 to 7.47; 1 RCT, 68 participants)
Myocardial infarction: no events in 2 trials (175 participants)
Cerebrovascular accident: no events in 2 trials (175 participants)
Endophthalmitis: none of the studies reported endophthalmitis
Arterial hypertension: none of the studies reported arterial hypertension
Pain: none of the studies reported pain
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; PDR: proliferative diabetic retinopathy; RR: risk ratio; VEGF: vascular endothelial growth factor.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded for imprecision (-1) (wide CIs) and downgraded for indirectness (-1) (only 1 trial reported at 12 months and only 1 (other) trial reported loss of ≥ 3 lines).
2 Downgraded for indirectness (-1) (only 1 trial reported at 12 months and only 1 (other) trial reported gain of ≥ 3 lines) and downgraded for inconsistency (-1) (I2 = 73%).
3Downgraded for risk of bias (-1) (2 studies at high risk of bias in ≥ 1 domains) and downgraded for inconsistency (-1) (I2 = 66%).
4 Downgraded for risk of bias (-1) (2 studies at high risk of bias in≥ 1 domains, 3 studies at unclear risk of bias in≥ 3 domains) and downgraded for indirectness (-1) (only 1 study reported
at 12 months)
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D I S C U S S I O N
Summary of main results
The aim of this review was to evaluate the effectiveness and safety
of anti-VEGF in PDR. We included 18 RCTs with 1005 partici-
pants that needed laser or surgical treatment for PDR or the com-
plications of PDR.
People receiving anti-VEGF in association with laser or surgical
(vitrectomy) treatment for PDR were less likely to lose vision and
more likely to gain vision and on average had better visual acuity
at follow-up. They were less likely to have progression of DR and
less likely to experience vitreous or pre-retinal haemorrhage. The
size of the effects were of the same order of magnitude for use
of anti-VEGF associated with both laser and surgical treatment.
There was only one relatively small and inconclusive trial of use
of anti-VEGF at the time of cataract surgery in people with DR.
Overall completeness and applicability of
evidence
Participants included in the review presented PDR that needed
PRP (eight from18RCTs) or complications such as vitreous haem-
orrhage (nine from 18 RCTs) or cataracts that needed surgery (one
from 18 RCTs). The median follow-up was six months.
Few studies have been included that assessed our primary outcome
(gain or loss of 3 or more lines of ETDRS). The effects of regres-
sion of vascular proliferation were poorly reported, and quality of
life was not mentioned. Furthermore, the monitoring of partici-
pants was less than one year in most studies. However, there was
a sufficient number of studies that calculated visual acuity in log-
MAR (13 RCTs and 811 eyes) and presented data about vitreous
or pre-retinal haemorrhage (10 RCTs and 735 eyes).
The number of RCTs was variable between anti-VEGFs, and
bevacizumab (15 RCTs) was the most evaluated, followed by
ranibizumab (two RCTs) and pegaptanib (one RCT). Although
the level of assessment of these drugs was not the same, in the over-
all analysis there was no significant differences between subgroups
in visual acuity and vitreous or pre-retinal haemorrhage.
Our pre-specified outcomes were for 12 months’ follow-up. Only
two of the 18 included studies followed up to 12 months. We
did not find any evidence that the size of the effect was related to
length of follow-up (data not shown) but ideally, longer follow-
up would have been available.
We found five ongoing RCTs that, in the future, may resolve
doubts about the efficacy and safety of these drugs for PDR (
Characteristics of ongoing studies).
Quality of the evidence
The overall quality of evidence was low or very low in this review.
For themain outcome of best-corrected visual acuity at 12months,
we downgraded the quality of the evidence to ’very low’ because
it was an indirect assessment. In fact, no study reported loss/gain
of 3 or more lines at 12 months. Two studies reported at three
months, one of these studies reported loss/gain of 2 or more lines
and one study reported loss/gain of 3 or more lines; two studies
reported “deterioration”, whichwas not defined, one at sixmonths
and one at 12 months. Imprecise estimates of visual benefit were
also a reason for downgrading evidence on the primary outcome
expressions.
For other outcomes, we downgraded the quality of the evidence
because seven RCTs had high risk of bias. The high risk of bias
was due to not blinding the interventions (Ahn 2011; Ernst 2012;
González 2009), attrition bias (Ahmadieh 2009; Ernst 2012;
Ramos Filho 2011), and selective reporting (Ahmadieh 2009; Cho
2010; Preti 2014). Furthermore, only one trial specified the cal-
culation of the sample size (DRCR.Net 2013), and there was im-
balance between groups at baseline in one trial (Sohn 2012), and
participants of the control group were worse than the participants
of the experimental group at baseline.
Finally, for some outcomes, the results of the individual studies
were heterogeneous and, although we provided a pooled estimate,
we downgraded for inconsistency.
Potential biases in the review process
This review has methodological strengths, as it has been successful
in obtaining information from trial investigators. Although not
all have responded, most investigators have done so. We have also
made an exhaustive search of clinical trials (including those in
progress), and have assessed the risk of bias and extracted data in
a duplicate way.
However, this review is limited by the quality of RCTs, which
included a low number of participants and presented unclear or
high risk of bias. Furthermore, three studies were not included in
efficacy analysis because the fellow eye was used as a control group
(Ernst 2012; Mirshahi 2008; Preti 2014).
Wemade somemodifications to the protocol (Differences between
protocol and review), but did not consider that these changes will
have introduced bias.
Agreements and disagreements with other
studies or reviews
As far as we know, there are no systematic reviews that have as-
sessed overall anti-VEGFs for PDR. We found two systematic re-
views that assessed anti-VEGF as adjuvant of vitrectomy for PDR
(Zhang 2013; Smith 2011). Zhang 2013 included eight RCTs that
assessed efficacy and safety of bevacizumab in the short-term (less
than one month). The pooled results showed significant benefits
of bevacizumab in overall surgical time, less intraoperative bleed-
ing and less recurrent haemorrhage within the first month. The
Cochrane systematic review, Smith 2011, included four RCTs, but
the results of studies were not pooled due tomethodological issues.
However, the authors concluded that bevacizumabmay reduce the
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incidence of early postoperative vitreous cavity haemorrhage.
Our review has included not only studies about complications of
DR that required surgery, but also those trying to treat vascular
proliferation. For these reasons, our systematic review has pre-
sented a larger number of included studies and participants. The
results point in the same direction as Zhang 2013. However, the
quality of the evidence was low or very low and these results must
be treated with caution.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was very low or low quality evidence from randomised con-
trolled trials for the efficacy and safety of anti-vascular endothe-
lial growth factor (anti-VEGF) drugs when used to treat prolifer-
ative diabetic retinopathy (PDR) over and above current standard
treatments. However, the results suggested that anti-VEGFs can
reduce the risk of intraocular bleeding in people with PDR.
Implications for research
There is a clear need for further adequate clinical trials to assess
efficacy of anti-VEGFs for PDR.
The unit of randomisation could be the eye, but for analysis, it
is preferable that only one eye is included per participant. The
calculations of sample size should be based on relevant clinical dif-
ferences. The concealment of interventions and a long-term fol-
low-up (at least 12 months) is necessary to improve the quality of
clinical trials. Future clinical trials should report data by subgroup
of PDR severity or haemorrhage at baseline, as there may be sub-
groups of people who benefit most.
We identified five ongoing trials registered with various tri-
als registries. Two of these studies are evaluating anti-VEGF
(ranibizumab in one study, aflibercept in one study) combined
with PRP versus PRP alone; two studies are evaluating beva-
cizumab as an addition to vitrectomy and one study is evaluating
aflibercept in cataract surgery.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmadieh 2009
Methods Study design: prospective, randomised, double-blind clinical trial of intravitreal beva-
cizumab for prevention of early post-vitrectomy haemorrhage in people with diabetes
Unit of randomisation: participant
Unit of analyses: the eye, but 1 eye only of each person was included in the study
Follow-up: 1 week and 1 month after surgery
Participants Country: Iran
Setting: Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences,
Tehran
Number of participants: 68 (68 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 34
Age (mean (SD)): 53.69 (11.7) years in bevacizumab plus vitrectomy group, 56.70 (10.
4) years in sham plus vitrectomy group
Gender: 34 men and 34 women
Inclusion criteria: indications for pars plana vitrectomia for complications of PDR existed
such as non-clearingVH,TRDinvolving or threatening themacula and active progressive
PDR
Exclusion criteria: BCVA of 20/40 or better, pregnancy, history of intravitreal beva-
cizumab injection, intraoperative use of long-acting gas or silicone oil, and simultaneous
intraocular surgery such as cataract extraction. Monocular participants
Interventions Treatment: intravitreal injection of bevacizumab 1.25 mg/0.05 mL 1 week before vit-
rectomy
Control: sham injection and vitrectomy
Duration: only 1 dose
Outcomes Primary: incidence of early (4 weeks) postoperative VH at 1 week and 1 month after
vitrectomy
Secondary: mean change in BCVA and any bevacizumab-related adverse event
Notes Funding: not reported
Trial registration: NCT00524875
Date conducted: not reported
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by
random block permutation according to a
computer-generated randomization list”
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Ahmadieh 2009 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Details of the series were unknown
to the investigators”
Comment: there was not specified the al-
location concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Subjects were masked to the treat-
ment method”
Comment: surgeons were not blinded to
the interventions assessed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Visual acuity was measured by an
optometrist whowasmasked to the groups.
All preoperative and postoperative exami-
nations were performed by one of the au-
thors (NS), who also was masked to the
study group identification”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were a 50% of losses dur-
ing the study
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
Ahn 2011
Methods Study design: prospective, randomised, clinical trial of intravitreal bevacizumab for pre-
venting postvitrectomy haemorrhage in PDR
Unit of randomisation: participant
Unit of analyses: the eye, but 1 eye of each participant was included in the study. How-
ever, if the study eye completed 6 months of follow-up, the contralateral eye requiring
vitrectomy also was allowed to enrol in this study. A total of 107 eyes of 91 participants,
of which there were 16 bilateral participants, were included for analysis
Follow-up: 1 day, 1 week, 1, 3 and 6 months after surgery
Participants Country: Korea
Setting: Department of Ophthalmology, Seoul National University College ofMedicine,
Seoul, Korea
Number of participants: 91 (107 eyes)
Exclusions post-randomisation: 2
Losses to follow-up: 17
Age (mean (SD)): 51.0 (9.5) years in preoperative bevacizumab group, 55.6 (SD 10.3)
years in intraoperative bevacizumab group, 55.0 (11.4) years in control group
Gender: 60 men and 47 women
Inclusion criteria: people that needed pars plana vitrectomy due to PDR-related com-
plications such as non-clearing VH, macula-involving or macula-threatening TRD or
fibrovascular proliferation with vitreoretinal adhesions
Exclusion criteria: follow-up period of < 6 months, intraoperative use of long-acting
gas or silicone oil, repeat vitrectomy after first vitrectomy for retinal diseases other than
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Ahn 2011 (Continued)
VH, previous history of vitrectomy, uncontrolled hypertension, medical history of blood
coagulopathy, interval between bevacizumab injection and pars plana vitrectomy > 2
weeks, or < 3 months of bevacizumab treatment
Interventions Treatment group 1 - preoperative bevacizumab: intravitreal bevacizumab 1.25 mg/0.05
mL injection 1-14 days before postoperative VH
Treatment group 2 - intraoperative bevacizumab: intravitreal bevacizumab 1.25 mg/0.
05 mL injection at the end of postoperative VH
Control: no injection and vitrectomy
Duration: only 1 dose
Outcomes Primary: incidence of early (4 weeks) and late (4 weeks) recurrent VH
Secondary: initial time of vitreous clearing, BCVA at 6 months after surgery and adverse
events
Notes Funding: not reported
Trial registration: NTC00745498
Date conducted: not reported
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomizationwas carried out us-
ing permuted block randomization with
equal allocation ratio”
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the lack of double-masking, leav-
ing room for possible bias”
Comment: the authors say the study was
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “the lack of double-masking, leav-
ing room for possible bias”
Comment: the authors say the study was
not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were 0 losses
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
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Cheema 2009
Methods Study design: prospective, randomised, clinical trial of intravitreal bevacizumab in
cataract surgery for preventing progression of diabetic retinopathy
Unit of randomisation: participant
Unit of analyses: the eye, but 1 eye of each participant was included in the study
Follow-up: 1 day; 1, 2 and 4 weeks and then at monthly intervals for 6 months
Participants Country: Saudi Arabia
Setting: hospital, Dhahran, Kingdom of Saudi Arabia
Number of participants: 68 (68 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean): 66.14 years in bevacizumab group, 64.5 years in control group
Gender: 43 men and 25 women
Inclusion criteria: cataract in people with diabetes with poor fundus view with 1. the
presence of clinically significant macular oedema, 2. mild, moderate, severe or very severe
non-PDR or PDR or 3. a combination of 1 and 2; people with previous focal or grid
laser photocoagulation for macular oedema
Exclusion criteria: eyes with glaucoma, uveitis and age-related macular degeneration or
a history of trauma or ocular surgery; people with previous panretinal laser photocoag-
ulation
Interventions Treatment: phacoemulsification with intraocular lens implantation and intravitreal be-
vacizumab 1.25 mg at the end of surgery
Control: phacoemulsification with intraocular lens implantation alone
Duration: only 1 dose
Outcomes Primary: progression of postoperative diabetic retinopathy and diabetic maculopathy
during a 6-month follow-up
Secondary: change in BCVA, changes in central macular thickness andmacular thickness
determined by optical coherence tomography, postoperative laser therapy, progression
to neovascular glaucoma
Notes Funding: not reported
Trial registration: not reported
Date conducted: the participants were recruited between February and December 2007
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomized to
a standardized procedure of phacoemulsifi-
cation with IOL [intraocular lens] implan-
tation alone (control group) or to receive
1.25mg intravitreal bevacizumab (Avastin)
at the end of surgery (intervention group)”
Comment: not described how it was gen-
erated the random
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Cheema 2009 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Progression of DR [diabetic
retinopathy] was based on assessment in a
masked fashion by 2 retina specialists (R.
A.C., Y.M.A.)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were 0 losses
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
Cho 2010
Methods Study design: prospective, randomised, clinical trial of intravitreal bevacizumab and
intravitreal triamcinolone as adjunctive treatments to PRP in diabetic retinopathy
Unit of randomisation: eye
Unit of analyses: eye
Follow-up: 1 day, 1 week, 1 and 3 months
Participants Country: Korea
Setting: Department of Ophthalmology, Konkuk University Medical Center, Konkuk
University School of Medicine, Seoul, Republic of Korea
Number of participants: 76 (91 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (SD)): 50.96 (46.0) years in bevacizumab group, 51.06 (26.0) years in tri-
amcinolone group
Gender: 55 men and 21 women
Inclusion criteria: aged ≥ 18 years, very severe non-PDR to high-risk PDR, Snellen
BCVA of ≥ 3
Exclusion criteria: blood pressure > 180 mmHg (systolic) and > 110 mmHg (diastolic),
glycated haemoglobin levels > 9.5%, chronic renal failure,major surgery within 1month,
or previous systemic steroids or anti-VEGF treatment. Ocular conditions other than
diabetic retinopathy (e.g. retinal vein occlusion, uveitis or other ocular inflammatory
disease, neovascular glaucoma, etc.). History of treatment for diabetic macular oedema,
PRPor focal/grid laser photocoagulation, or previous intraocular surgery, or uncontrolled
glaucoma in the last 3 months
Interventions Treatment group 1: intravitreal bevacizumab 1.25 mg/0.05 mL, 1 week before PRP
Treatment group 2: intravitreal triamcinolone 4 mg/0.1 mL, 1 day after PRP
Control: PRP
Duration: only 1 dose
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Cho 2010 (Continued)
Outcomes Primary: changes in BCVA and central macular thickness at 1 and 3 months
Secondary: proportion of visual gain or loss, decreased or increased central macular
thickness, adverse events
Notes Funding: no financial interest of the authors
Trial registration: not reported
Date conducted: March 2007 to August 2008
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses
Selective reporting (reporting bias) High risk Comment: incomplete results of the prin-
cipal variable were described in the meth-
ods section
Di Lauro 2010
Methods Study design: prospective, randomised, clinical trial of intravitreal bevacizumab for sur-
gical treatment of severe PDR
Unit of randomisation: participant
Unit of analyses: eye/participant
Follow-up: 1, 6, 12 and 24 weeks after the surgery
Participants Country: Italy
Setting: Department of Ophthalmology, Hospital C.T.O. of Naples, Naples, Italy
Number of participants: 68 (72 eyes)
Exclusions post-randomisation: 3 (regression of the haemorrhage in a bevacizumab
group)
Losses to follow-up: 0
Age: not reported
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Di Lauro 2010 (Continued)
Gender: not reported
Inclusion criteria: people affected by VH and TRD consequent to active PDR
Exclusion criteria: people with neovascular glaucoma or cataract (or both) and cases
of combined traction and rhegmatogenous retinal diabetes (diagnosed either before or
during the surgery)
Interventions Treatment group 1: intravitreal bevacizumab 1.25 mg/0.05mL, 7 days before vitrectomy
Treatment group 2: intravitreal bevacizumab 1.25 mg/0.05 mL, 20 days before vitrec-
tomy
Control: sham injection 20 days before vitrectomy
Duration: only 1 dose
Outcomes Primary: clearing of VH, incidence of adverse effects and the need of other procedures
during the surgery
Secondary: change in BCVA and duration of surgery
Notes Funding: not reported
Trial registration: NCT01025934
Date conducted: October 2005 to May 2007
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients in group A [control] were
given a subconjunctival injection of 0.05
ml of BSS (Blood saline serum) 3 weeks
before the vitrectomy”
Comment: control received a sham inter-
vention. The participant was blind to the
treatment received. However, it is possible
that the personnel that administered the
sham were aware of treatment because the
site of application was subconjunctival and
not intravitreal as with bevacizumab
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients in group A [control] were
given a subconjunctival injection of 0.05
ml of BSS (Blood saline serum) 3 weeks
before the vitrectomy”
Comment: control received a sham inter-
vention. The outcome assessor was blinded
to the treatment administered
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Di Lauro 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were 3 losses post-randomisation,
but losses during follow-up were not noted
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
reported in the methods section
DRCR.Net 2013
Methods Study design: phase 3, double-blind, randomised, multicentre clinical trial of intravitreal
ranibizumab for VH from PDR
Unit of randomisation: eye (1 eye per participant)
Unit of analyses: eye
Follow-up: at 4, 8, 12 and 16 weeks
Participants Country: USA
Setting: community-based and academic-based ophthalmology practices specialising in
retinal diseases (61 centres)
Number of participants: 261 (261 eyes)
Exclusions post-randomisation: 10 (3 in ranibizumab group and 7 in the control group)
Losses to follow-up: 4 (2 in each group)
Age (mean (SD)): 58 (12) years
Gender: 52% women
Inclusion criteria: ≥ 18 years of age with type 1 or type 2 diabetes. Eyes with VH
associated to PDR, causing vision impairment and precluding completion of PRP
Exclusion criteria: eyes requiring immediate vitrectomy for reasons such as rhegmatoge-
nous or traction retinal detachment; vision of no light perception, neovascular glaucoma,
active iris neovascularisation judged or angle neovascularisation; history of intravitreal
anti-VEGF treatment for VH
Interventions Treatment: intravitreal ranibizumab 0.5 mg at baseline and 4 and 8 weeks
Control: intravitreal saline at baseline and 4 and 8 weeks
Both groups received PRP as soon as possible after the first injection
Duration: 3 doses
Outcomes Primary: cumulative probability of vitrectomy performed within 16 weeks
Secondary: the proportion of eyes with “complete” PRP by 16 weeks in the absence of
vitrectomy; improvement in visual acuity from baseline to the 12-week follow-up visit;
extent of VH measured by optical coherence tomography signal strength; systemic and
ocular adverse events
Notes Funding: co-operative agreements EY14231 and EY18817 from the National Eye Insti-
tute and the National Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health, Department of Health and Human Services (USA). Genentech
provided the ranibizumab for the study and provided funds to DRCR.net
Trial registration: NCT00996437
Date conducted: June 2010 to March 2012
Conflict of interest: Genentech provided the ranibizumab for the study and provided
funds to DRCR.net to defray the study’s clinical site costs. DRCR.net had complete
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DRCR.Net 2013 (Continued)
control over the design of the protocol, conduct, and reporting of the research and
retained ownership of the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: it was not specifiedhow the ran-
dom sequence was generated. Only spec-
ified that used a permuted block design
stratified by site
Allocation concealment (selection bias) Low risk Quote: “randomly assigned on the DRCR.
net website”
Comment: the randomisation was cen-
tralised and the investigator were blinded
to the random sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “eyes received an injection of saline
or 0.5-mg ranibizumab at randomization,
4 weeks, and 8 weeks using a masked vial
provided by the Coordinating Center that
was identified by number only”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “eyes received an injection of saline
or 0.5-mg ranibizumab at randomization,
4 weeks, and 8 weeks using a masked vial
provided by the Coordinating Center that
was identified by number only”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: the analyses were by intention
to treat, and there were 4 losses of follow-
up (2 in each group)
Selective reporting (reporting bias) Low risk Comment: the results of the outcomeswere
specified in the methods section
El-Batarny 2008
Methods Study design: prospective, randomised trial of intravitreal bevacizumab as an adjunctive
treatment before diabetic vitrectomy
Unit of randomisation: participant
Unit of analyses: eye/participant
Follow-up: 1 day, 1 week, 2 weeks, 1 month after surgery and monthly up to the end of
the follow-up (mean 12 months; range 7-18 months)
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El-Batarny 2008 (Continued)
Participants Country: Sultanate of Oman
Setting: Magrabi Eye and Ear Hospital, Muscat, Sultanate of Oman
Number of participants: 30 (30 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (SD)): 44 (11) years in bevacizumab plus vitrectomy group, 46 (12) years in
vitrectomy alone group
Gender: not reported
Inclusion criteria: people with indications for vitrectomia for complications of PDR
existed such as TRD involving or treating the macula, not resolving VH, pre-retinal
subhyaloid bleeding
Exclusion criteria: not reported
Interventions Treatment: intravitreal injection of bevacizumab 1.25 mg/0.05 mL, 5-7 days before
vitrectomy
Control: vitrectomy alone
Duration: only 1 dose
Outcomes Primary: feasibility of the surgery and postoperative complications
Secondary: visual acuity at 6months of follow-up, any bevacizumab-related adverse event
Notes Funding: not reported
Trial registration: not reported
Date conducted: not reported
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were 0 losses
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
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Ergur 2009
Methods Study design: prospective, randomised clinical trial of intravitreal bevacizumab for PDR
Unit of randomisation: participant
Unit of analyses: eye
Follow-up: 1 day, 1 week, 1 and 6 months
Participants Country: Turkey
Setting:M.D.,Ministry of Health AtatürkResearch and Training Hospital 2st EyeClinic
Ankara, Turkey
Number of participants: 16 (19 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (SD)): 71.4 (4.6) years in bevacizumab plus PRP group, 68.3 (3.4) years in
PRP group
Gender: 9 men and 7 women
Inclusion criteria: people with PDR
Exclusion criteria: people with history of cataract surgery or thromboembolic ictus
Interventions Treatment: intravitreal bevacizumab 1.25 mg/0.05 mL, 20 days before PRP, 3 sessions
Control: PRP/week/3 weeks, 3 sessions
Outcomes Primary: BCVA, intraocular pressure, biomicroscopic examination, fundus examination,
colour fundus photography, fluorescein leakage areas
Notes Funding: not reported
Trial registration: not reported
Date conducted: not reported
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were 0 losses
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Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
Ernst 2012
Methods Study design: prospective, randomised, clinical trial of intravitreal bevacizumab for treat-
ment of naive PDR and severe non-PDR
Unit of randomisation: eye
Unit of analyses: eye
Follow-up: 1, 2, 6 and 12 months
Participants Country: Mexico
Setting: Asociación para Evitar la Ceguera en México
Number of participants: 15 (20 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 5
Age (mean (SD)): 53.3 (9) years
Gender: 4 men and 6 women
Inclusion criteria: people with type 2 diabetes mellitus and symmetric untreated severe
naive PDR or PDR without macular oedema or prior intraocular surgery
Exclusion criteria: people with history of myocardial infarction or cerebrovascular acci-
dent, retinal detachment, VH, previous treatment for diabetic retinopathy, media opac-
ities that precluded visualisation of the fundus, pregnancy and inability to understands
the implications of the protocol
Interventions Treatment: intravitreal bevacizumab 2.5 mg/0.1 mL every 2 months for 12 months (6
injections in total)
Control: PRP, 2 sessions. A third session was administered if there was neovascularisation
Outcomes Primary: BCVA, macular thickness, median deviation in visual fields at 1 year, and score
on a participant satisfaction scale at 6 months and 1 year
Secondary: complications associated to the treatments
Notes Funding: not reported
Trial registration: NCT00347698
Date conducted: March 2006 to August 2007
Conflict of interest: none reported
This study was designed using both treatments in the same participant: intravitreal
bevacizumab in 1 eye compared with PRP in the contralateral eye
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the right eye was randomly as-
signed to treatment with PRP or intravit-
real bevacizumab, and the left eye received
the other treatment”
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Ernst 2012 (Continued)
Comment: not reported
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: open-label study
Incomplete outcome data (attrition bias)
All outcomes
High risk The initial number of participants was 30,
but only 15 participants were included and
there was 5 losses
Selective reporting (reporting bias) High risk Some results of variables specified in the
published protocol were not reported: me-
dian deviation in visual fields at 1 year, and
score on a participant satisfaction scale at 6
months and 1 year
Farahvash 2011
Methods Study design: randomised, clinical trial in people with diabetes with indication for vit-
rectomy
Unit of randomisation: participant
Unit of analyses: participant/eye
Follow-up: first day, first week, first month, and then every 3 months until the last visit.
Median: 8 months (range 3-15 months)
Participants Country: Iran
Setting: hospital
Number of participants: 35 (35 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (range)): 58 (37-73) years
Gender: 18 men and 17 women
Inclusion criteria: people with indications for vitrectomy. The indications were ”persis-
tent vitreous hemorrhage >1 month in a patient with no history of PRP, nonclearing
vitreous hemorrhage in a patient with history of complete PRP, vitreous hemorrhage with
neovascularization of iris, vitreous hemorrhage with glaucoma, and vitreous hemorrhage
with retinal detachment (based on the echography)“
Exclusion criteria: ”history of vitrectomy or any intraocular injection in the study eye
or history of IVB [intravitreal bevacizumab injection] in either eye, previous myocardial
infarction, cerebrovascular accident or thromboembolic event, uncontrolled hyperten-
sion, coagulation abnormalities, or current use of any anticoagulants but aspirin (aspirin
was discontinued 1 week before injection) and those with unstable medical conditions“
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Farahvash 2011 (Continued)
Interventions Treatment: intravitreal injection bevacizumab 1.25 mg 7 days prior to surgery
Control: no treatment before surgery and vitrectomy
Duration: only 1 dose
Outcomes Primary: severity of intraoperative bleeding and break formation (based in surgeons
observation)
Secondary: visual acuity, complete attachment of the retina, complications
Notes Funding: not reported
Trial registration: not reported
Date conducted: January 2008 to January 2009
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”in each subgroup, the patients
were randomly assigned to injection of be-
vacizumab preoperatively (injection group)
or not (control group)
Comment: not described the method of
randomization
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “the surgeons were masked regard-
ing patient groups and subgroup”
Comment: not clear if the participantswere
blinded to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the surgeons were masked regard-
ing patient groups and subgroup”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no losses for the
main outcome
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in themethods section. SDof the
BCVA after intervention were missing
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González 2009
Methods Study design: randomised, prospective, open-label direct comparison of pegaptanib alone
with PRP alone in people with PDR
Unit of randomisation: eyes (Quote: “for subjects in whom both eyes were eligible, one
eye was selected randomly as the study eye. Fellow eyes of these subjects were treated
according to standard clinical guidelines established”)
Unit of analyses: eye
Follow-up: 30 weeks
Participants Country: USA
Setting: Valley Retina Institute
Number of participants: 20 (20 eyes)
Exclusions post-randomisation: 1
Losses to follow-up: 3
Age (mean): 56.2 years in intravitreal pentaganib group, 59 years in PRP group
Gender: 13 men and 7 women
Inclusion criteria: active PDR, in 1 or both eyes, with at least 1 of the following high-
risk characteristics as defined by the Diabetic Retinopathy Study: 1. new vessels within
1 disc diameter of the optic nerve head that were larger than one-third of the disc area;
2. VH or pre-retinal haemorrhage associated with either less extensive new vessels at the
optic disc, or with new vessels elsewhere half the disc area or larger; or both 1. and 2
Exclusion criteria: haemorrhage or media opacity obscuring visualisation of the macula
and optic nerve; epiretinal membranes involving the macula; proliferative diabetic mem-
branes along the major retinal arcades sufficiently extensive to cause either significant
vitreomacular traction or significant impairment in BCVA; any TRD; severe ischaemia
involving the foveal avascular zone; neovascular glaucoma; study eye treated with intrav-
itreal steroid injections within 6 months prior to baseline or PRP treatment within 90
days of baseline (or both)
Interventions Treatment: intravitreal pentaganib 0.3 mg every 6 weeks for 30 weeks
Control: PRP laser every 6 weeks for 30 weeks
Outcomes Primary: regression of PDR from baseline to week 36, defined as regression of neovas-
cularisation of the optic disc , neovascularisation elsewhere, or both
Secondary: BCVA assessed by ETDRS letter score, as well as changes in optical coherence
tomography assessments of central macular thickness and macular volume
Notes Funding: grant from Pfizer, New York and (OSI) Eyetech, New York
Trial registration: not reported
Date conducted: not reported
Conflict of interest: first author was a paid consultant and speaker for (OSI) Eyetech
Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “eligible eyes were randomly as-
signed (1:1) to either pegaptanib alone or
PRP alone based on a sequence generated
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by the random number function in Mi-
crosoft Excel (MicrosoftCorporation, Seat-
tle, Washington)”
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “prospective, randomised, con-
trolled, open-label, exploratory study”
Comment: the participants and personnel
were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “prospective, randomised, con-
trolled, open-label, exploratory study”
Comment: the outcome assessor was not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 4 losses (2 in each group)
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
Mirshahi 2008
Methods Study design: prospective, randomised, double-blind clinical trial of intravitreal beva-
cizumab in PDR
Unit of randomisation: eye
Unit of analyses: eye
Follow-up: 6 and 16 weeks
Participants Country: Iran
Setting: EyeResearchCenter, Farabi EyeHospital,Medical Sciences/University ofTehran
Number of participants: 40 (80 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (median (range)): 52 (39-68) years
Gender: 12 men and 28 women
Inclusion criteria: people with high-risk characteristics identified by Diabetic Retinopa-
thy Study criteria: neovascularisation of the disc ≥ one-quarter to one/third disc area,
any amount of disc neovascularisation with VH or pre-retinal haemorrhage, or neovas-
cularisation elsewhere ≥ one-half disc area with VH or pre-retinal haemorrhage (with
or without macular oedema)
Exclusion criteria: people with uncontrolled hypertension, recent (in the past 6 months)
myocardial infarction or cerebrovascular accident, uncontrolled glaucoma, a history of
any type of retinal photocoagulation, a diagnosis of TRD
Interventions Treatment: intravitreal injection bevacizumab 1.25 mg/0.05 mL at the first session of
laser photocoagulation and 3 sessions of laser photocoagulation (1 week apart)
Control: sham injection in the fellow eye at the first session of laser photocoagulation
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and 3 sessions of laser photocoagulation (1 week apart)
Duration: only 1 dose
Outcomes Primary: regression response was defined angiographically
Secondary: recurrence of PDR and complications of treatment
Notes Funding: not reported
Trial registration: not reported
Date conducted: December 2005 to September 2006
Conflict of interest: none reported
This study was designed using both treatments in the same participant: intravitreal
bevacizumab in 1 eye compared with PRP in the contralateral eye
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “fellow eyes of each case were ran-
domly assigned to receive Avastin [beva-
cizumab] or sham”
Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “fellow eye injection was mimicked
with a needleless syringe”
Comment: personnel were not blinded, but
the participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “this assessment was carried out by
two independent masked observers; in case
of conflict it was resolved through discus-
sion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 0 losses
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
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Modarres 2009
Methods Study design: prospective surgeon-blinded randomised clinical trial in people undergoing
pars plana vitrectomy for complications of PDR
Unit of randomisation: eye
Unit of analyses: eye
Follow-up: mean (SD) 7 (3.6) months
Participants Country: Iran
Setting: Department of Ophthalmology
Number of participants: 40 (40 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (SD)): 55.8 (11.3) years in bevacizumab group, 53.2 (SD 11.7) years in
control group
Gender: not reported
Inclusion criteria: people with diabetes who were candidates for vitrectomy with com-
plexity scores of 4-8
Exclusion criteria: presence of significant cataract that caused impairment of vision, pre-
vious vitreoretinal surgery, previous intravitreal bevacizumab injection and the presence
of any other vitreoretinal pathology
Interventions Treatment: intravitreal bevacizumab 2.5 mg 3-5 days before operation
Control: no preoperative injection was performed
Duration: only 1 dose
Outcomes Primary: facilitation of the surgery (number of endodiathermy applications, backflush
needle applications, duration of surgery, type of tamponade) and decrease of complica-
tions (postoperative VH)
Secondary: anatomic and visual outcomes (3-month postoperative BCVA aswell as visual
acuity at the last follow-up)
Notes Funding: not reported
Trial registration: not reported
Date conducted: not reported
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “prospective surgeon-masked ran-
domized clinical trial. The surgeons (MM,
MH, MN, and MMP) were masked as to
injection.During each operation, the num-
ber of endodiathermy applications, back-
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Modarres 2009 (Continued)
flush needle applications, and the duration
of surgerywere recordedby an independent
observer”
Comment: the blinding of the participants
was not mentioned. The participants were
either given an injection or not of be-
vacizumab. Therefore, they would know
which group they were in
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “prospective surgeon-masked ran-
domized clinical trial. The surgeons (MM,
MH, MN, and MMP) were masked as to
injection.During each operation, the num-
ber of endodiathermy applications, back-
flush needle applications, and the duration
of surgerywere recordedby an independent
observer”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses during follow-up were not reported
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
Preti 2014
Methods Study design: prospective, randomised, blinded, controlled trial comparing of PRP with
intravitreal bevacizumab injections versus PRP alone in high-risk PDR
Unit of randomisation: eye, within-person study
Unit of analyses: eye but not pair-matched analysis
Follow-up: 6 months
Participants Country: Brazil
Setting: Department of Ophthalmology, University of Sap Paulo Medical School
Number of participants: 42 (84 eyes)
Exclusions post-randomisation: 7 people with VH
Losses to follow-up: 0
Age (mean (range)): 56 (43-73) years
Gender: 28 men and 14 women
Inclusion criteria: aged ≥ 18 years, high-risk PDR with or without diabetic macular
oedema; visual acuity ≥ 20/200
Exclusion criteria: pretreatment for diabetic retinopathy (laser, intraocular medications
and surgeries); pre-retinal haemorrhage and VH; presence of changes in the vitreous-
retinal interface (epiretinalmembrane,macular hole and vitreoretinal traction syndrome)
; evidence of active external eye infection such as blepharitis; prior thromboembolic
events, including myocardial infarction, stroke and deep vein thrombosis; systolic blood
pressure > 180mmHg and diastolic blood pressure > 110mmHg; glycated haemoglobin
levels > 15%; chronic renal failure; major surgery within 1 month; previous systemic
anti-VEGF
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Interventions Treatment: 2 intravitreal bevacizumab injections 1.25 mg/0.05 mL, 1 dose 1 week before
the PRP, and the other dose after the last session of PRP. The PRP was performed weekly
over 3 weeks
Control: PRP performed weekly over 3 weeks
Duration: 4 weeks
Outcomes Primary: changes in contrast sensitivity measured with Vistech Consultants Incorpora-
tion® (VCTS) at 1, 3 and 6 months between the groups with and without diabetic
macular oedema
Secondary: changes in VCTS within each group with and without diabetic macular
oedema; ocular safety (ocular hypertension, lens opacity progression and anterior cham-
ber reaction arterial); systemic safety (thromboembolic events)
Notes Funding: study was supported by the Sao Paulo Research Foundation (FAPESP) No
2009/08895-1
Trial registration: NCT01389505
Date conducted: February 2011 to June 2012
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: blinding not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7 post-randomisation losses, not specified
by group
Selective reporting (reporting bias) High risk Comments: outcome measures on clinical
trials.gov were different to those reported
in the paper:
Primary outcome measures: functional
macular evaluation [timeframe: 24 weeks]
[designated as safety issue: yes]; during this
24weeks of follow-up the visual acuity (ET-
DRS), contrast vision will be measured at
baseline, 4, 12 and finally at 24 weeks
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Secondary outcome measures: structural
macular evaluation [timeframe: 24 weeks]
[designated as safety issue: yes]; during the
24 weeks of follow-up the following mea-
sured will be made: optical coherence to-
mography
Ramos Filho 2011
Methods Study design: randomised, clinical trial that assessed efficacy of ranibizumab in people
with high-risk PDR
Unit of randomisation: participant
Unit of analyses: participant/eye
Follow-up: 16, 32 and 48 weeks
Participants Country: Brazil
Setting: Department of Ophthalmology, School of Medicine
Number of participants: 40 (40 eyes)
Exclusions post-randomisation: 1
Losses to follow-up: 10
Age (mean): 50.5 years in ranibizumab plus PRP group, 63.3 years in PRP alone group
Gender: 18 men and 11 women
Inclusion criteria: people with high-risk PDR, which was defined according to the guide-
lines set forth by the ETDRS: 1. presence of neovascularisation at the disc > ETDRS
standard photograph 10A, 2. presence of neovascularisation at the disc associated with
VH or pre-retinal haemorrhage or 3. neovascularisation elsewhere with more than one-
half disk area associated with VH or pre-retinal haemorrhage
Exclusion criteria: 1. history of prior laser treatment or vitrectomy in the study eye;
2. history of thromboembolic event, 3. major surgery within the prior 6 months or
planned within the next 28 days; 4. uncontrolled hypertension, 5. known coagulation
abnormalities or current use of anticoagulative medication other than aspirin or 6. any
condition affecting documentation
Interventions Treatment: intravitreal ranibizumab 0.5 mg, 60 minutes after the completion of PRP
Control: PRP
Duration: only 1 dose
Outcomes Primary: total area (mm2) of fluorescein leakage from active neovascularisation
Secondary: BCVA (logMAR) and the central subfield macular thickness
Notes Funding: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). Grant
number: 2009 01036-3
Trial registration: NCT01988246
Trial registration: not reported
Date conducted: February 2009 to December 2009
Conflict of interest: none reported
Risk of bias
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Ramos Filho 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The technician was asked to pick
up one of two identical opaque envelopes;
one contained the designation for PRP, and
the other contained the designation for
PRP plus treatment”
Comment: the method of randomisation
was not described. There was an imbalance
between groups in the age of the partici-
pants (mean (SD): 63.3 (2.5) with intravit-
real ranibizumab + PRP vs. 50.5 (3.0) with
PRP alone; P value = 0.0036)), which sug-
gest doubts about if theywere correctly ran-
domised
Allocation concealment (selection bias) Low risk Quote: “the technicianwas asked topick up
one of two identical opaque envelopes; one
contained the designation for PRP, and the
other contained the designation for PRP
plus treatment”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: blinding of participants and
personnel were not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a single masked certified ex-
aminer performed Early Treatment Dia-
betic Retinopathy Study (ETDRS) best-
corrected visual acuity (BCVA) measure-
ments prior to any other study procedure. A
single retinal specialist performed the oph-
thalmic evaluations (JARF) and the stereo-
scopic fundus photography (FPPA). Study
data were analysed and interpreted by AM,
RAC, IUS, JASR, RJ”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “twenty-nine of 40patients initially
included in this trial completed the 48-
week follow-up evaluation”
Comment: there were 11 losses (27.5%)
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
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Rizzo 2008
Methods Study design: randomised clinical trial in people undergoing pars plana vitrectomy for
retinal detachment
Unit of randomisation: participant
Unit of analyses: participant/eye
Follow-up: 6 months
Participants Country: Italy
Setting: Eye Surgery Clinic
Number of participants: 22 (22 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (range)): 52 (24-63) years
Gender: not described
Inclusion criteria: TRD, tractional-rhegmatogenous retinal detachment or tractional
detachment complicated with VH
Exclusion criteria: history of vitrectomy in the study eye, thromboembolic events, major
surgery within the previous 3 months or planned within the next 28 days, uncontrolled
hypertension, known coagulation abnormalities or current use of anticoagulative medi-
cation other than aspirin
Interventions Treatment: intravitreal bevacizumab 1.25 mg/0.05 mL, 5-7 days before surgery
Control: no preoperative injection
Duration: only 1 dose
Outcomes Primary: feasibility of the surgery
Secondary: visual and anatomic outcome at 6 months
Notes Funding: not reported
Trial registration: not reported
Date conducted: not reported
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “we used a table of random num-
bers in order to assign each study partici-
pant to group 1 or 2”
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: not described
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Rizzo 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there were 0 losses
Selective reporting (reporting bias) Unclear risk Comment: there was no complete data for
BCVA (SD)
Sohn 2012
Methods Study design: randomised double-blind clinical trial
Unit of randomisation: eye
Unit of analyses: eye
Follow-up: 3 months
Participants Country: USA
Setting: Department of Ophthalmology
Number of participants: 19 (20 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 2
Age (mean (range)): 52 (31-64) years
Gender: 12 men and 7 women
Inclusion criteria: people with TRD or combined TRD/rhegmatogenous retinal detach-
ment secondary to PDR who were given anaesthesia clearance for pars plana vitrectomy.
Indications for pars plana vitrectomy included TRD involving the macula, TRD/rheg-
matogenous retinal detachment and non-clearing or recurrent VH precluding complete
PRP with TRD not necessarily involving the macula
Exclusion criteria: history of pars plana vitrectomy; dense VH preventing preoperative
grading of fibrovascular membranes; an inability to return for pars plana vitrectomy
within 3-7 days after randomisation; a history of cerebrovascular accident, thromboem-
bolic event or myocardial infarction within 6 months; aged < 18 years and pregnancy
Interventions Treatment: intravitreal bevacizumab injection 1.25 mg/0.05 mL, 3-6 days before surgery
Control: sham injection (1 syringe without a needle placed to simulate intravitreal in-
jection)
Duration: only 1 dose
Outcomes Primary: visual acuity at 3 months of follow-up, vitreous levels of VEGF
Secondary: amount of intraoperative bleeding
Notes Funding: supported by: the Eugene de Juan Jr Award for Innovation (Dr Sohn); theHeed
Foundation (Drs Kim and Javaheri); grant K12-EY16335 from the National Eye Insti-
tute, National Institutes of Health (Dr Kim); The Arnold and Mabel Beckman Foun-
dation (Dr Hinton); Research to Prevent Blindness (Department of Ophthalmology,
University of Iowa Hospitals and Clinics); and core grant EY03040 from the National
Eye Institute (Doheny Eye Institute)
Trial registration: not reported
Date conducted: not reported
Conflict of interest: Dr Hinton served as a consultant to FibroGen, Inc. Dr Eliott served
as an ad hoc consultant to Genentech
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Sohn 2012 (Continued)
Other comments: participants of the control group had more severe symptoms than
the bevacizumab group at baseline: 2 had visually significant cataract (1 participant in
each group), 2 had worsening ischaemia (in control group), 1 had severe neovascular
glaucoma (in control group) and 1 had VH (in control group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the patient and surgeon were
masked to the patients’ randomization
group”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the patient and surgeon were
masked to the patients’ randomization
group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: only 2 participants (1 in each
group) were lost during the follow-up
Selective reporting (reporting bias) Low risk Comment: the results of the variables were
described in the methods section
Zaman 2013
Methods Study design: randomised, controlled trial comparing intravitreal bevacizumab injection
5-7 days prior to pars plana vitrectomy versus pars plana vitrectomy alone
Unit of randomisation: participant
Unit of analyses: participant
Follow-up: 6 months
Participants Country: Pakistan
Setting: Al-Ibrahim Eye Hospital
Number of participants: 54 (54 eyes)
Exclusions post-randomisation: 0
Losses to follow-up: 0
Age (mean (range)): 52 (39-67) years
Gender: 32 men and 22 women
Inclusion criteria: non-clearing VH of at least 1 month; TRD involving or threatening
the macula; pre-retinal subhyaloid bleeding covering the macula
Exclusion criteria: not reported
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Zaman 2013 (Continued)
Interventions Treatment: intravitreal bevacizumab 1.25 mg/0.05 mL (Avastin, Genentech), 5-7 days
before PPV. Topical antibiotic (moxifloxacin) was started 1 day before the procedure and
was continued for 3 days post injection
Control: PPV alone
Duration: only 1 dose
Outcomes Primary: improvement of BCVA after surgery, postoperative complications, hyphema,
rubeosis, frequency of VH. Early postoperative VH was taken as VH occurring within 4
weeks after surgery. Later postoperative VH was taken as VH occurring within 5 weeks
and 6 months
Notes Funding: not reported
Trial registration: not reported
Date conducted: September 2010 to August 2011
Conflict of interest: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “all cases completed a minimum
follow up of 6 months”
Comment: there were no losses
Selective reporting (reporting bias) Low risk Comment: in the paper the results of out-
comes were specified in the methods sec-
tion, but we have not access to the protocol
to check if all outcomes were reported
BCVA: best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; PDR: proliferative diabetic retinopathy;
PRP: panretinal photocoagulation; SD: standard deviation; TRD: tractional retinal detachment; VEGF: vascular endothelial growth
factor; VH: vitreous haemorrhage.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arimura 2009 Retrospective, comparative study
Fulda 2010 Not a randomised clinical trial. Each participant received the 2 evaluated interventions. The right eye
received intravitreal bevacizumab and 1 session of 800 scattered laser spots. The left eye underwent a full
1600 laser panretinal photocoagulation
Genovesi-Ebert 2007 Not a randomised clinical trial
Gonzalez 2006 RCT assessed the efficacy and safety of pegaptanib in treating diabetic macular oedema and diabetic
retinopathy. The publication was an abstract and there was insufficient information to include the study.
The principal focus is of participants with macular oedema
Hattori 2010 Not a randomised clinical trial
Huang 2009 Compared with historical controls. Not randomised
Ip 2012 2 years of follow-up to evaluate effects of intravitreal ranibizumab on diabetic retinopathy severity over time
in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) for diabetic macular oedema
Jiang 2009 Retrospective study
Jorge 2006 Non-randomised study
Lanzagorta-Aresti 2009 The included participants did not have proliferative diabetic retinopathy. The outcomes measured were
central macular thickness and visual acuity in participants with a moderate retinopathy not proliferative
that needed a cataract surgery
López-López 2012 Anti-VEGF group was not randomised
Michaelides 2010 Focus of the clinical trial was diabetic macular oedema
Minnella 2008 Non-controlled clinical trial
Scott 2008 Study evaluated agreement in diabetic retinopathy severity classification by retina specialists performing
ophthalmoscopy vs. reading centre grading of 7-field
stereoscopic fundus photographs in a phase 2 clinical trial of intravitreal bevacizumab for centre-involved
diabetic macular oedema
Shin 2009 Data were collected retrospectively
Stergiou 2007 Retrospective case series
Tonello 2008 Quote: “for patients (n= 8) presenting with high-risk PDR [proliferative diabetic retinopathy] in both
eyes, the eye with worse BCVA [best-corrected visual acuity] was selected to receive PRP [panretinal
photocoagulation] plus intravitreal bevacizumab (eight eyes) and the fellow eye was treated with PRP alone
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(Continued)
(eight eyes)”
Comment: clinical trial partially randomised
Yeh 2009 Not a randomised study. The treatment assignment was alternative
Zhou 2010 Focus of the clinical trial is diabetic macular oedema
Characteristics of ongoing studies [ordered by study ID]
EUCTR2013-003272-12-GB
Trial name or title EUCTR2013-003272-12-GB
Methods Prospective, randomised, controlled, single-masked study
Participants 220 participants with proliferative diabetic retinopathy
Interventions Aflibercept versus PRP laser treatment
Outcomes Primary:
1. Difference in mean change in BCVA measured in ETDRS letter scores
Secondary:
1. To measure the effect of intravitreal aflibercept therapy, relative to PRP on additional visual functions
and quality of life outcomes including:
i) unilateral and binocular Estermann visual fields defects
ii) binocular visual acuity and low luminance visual acuity
iii) visual acuity outcomes in terms of visual gain or loss
iv) contrast sensitivity using Pelli Robson charts
v) vision-related quality of life measured by VFQ-25 (Visual Functioning Questionnaire 25) and
RetDQoL ( Retinopathy-Dependent Quality of Life)
vi) diabetic retinopathy treatment satisfaction outcomes (RetTSQ; Retinopathy Treatment
Satisfaction Questionnaire)
vii) generic health-related quality of life using the EQ-5D, ICECAP-A (ICEpop CAPability measure
for Adults) and CSRI (Client Services Receipt Inventory)
2. To estimate incremental cost-effectiveness of intravitreal aflibercept versus standard PRP treatment at
52 weeks
3. To determine the proportions of treatment naive and post-treatment PRP eyes in both groups that do
not require PRP through 52 weeks after basic treatment of 3 loading doses of aflibercept or initial
completion of PRP
4. To compare between groups the regression pattern at 12 weeks and the regression and re-activation
patterns of retinal neovascularisation at 52 weeks
5. To compare the proportion of participants with 1-step and 3-step improvement or worsening of
diabetic retinopathy between treatment groups at 12 and 52 weeks as per schedule of assessment
6. To explore the difference in safety profile between intravitreal aflibercept and PRP at 52 weeks, in
terms of proportion of participants developing macular oedema (defined as central subfield thickness of >
300 µm on spectral domain optical coherence tomography due to clinical evidence of macular oedema), any
de novo or increase in existing vitreous haemorrhage, de novo or increasing tractional retinal detachment,
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EUCTR2013-003272-12-GB (Continued)
neovascular glaucoma and requirement for vitrectomy. The indication for vitrectomy will be reported
Starting date 8 April 2014
Contact information Natasha Ajraam. Moorfields Eye Hospital, London, UK
e-mail: natasha.ajraam@moorfields.nhs.uk
Notes Funding: Bayer PLC and NIHR MRC - EME grant
NCT01854593
Trial name or title NCT01854593
Methods Prospective, randomised, controlled, double-masked (participant and carer) study
Participants People with proliferative diabetic retinopathy and indication for primary vitrectomy
Interventions Intravitreal bevacizumab 0.16 mg versus sham injection
Outcomes VEGF concentration in vitreous after intravitreal bevacizumab injection at 1 year
Early (within 4 weeks) postoperative vitreous haemorrhage. Re-operation due to vitreous haemorrhage
Starting date May 2012
Contact information Ayumu Manabe. Nihon University, Japan
Notes
NCT01941329 (PROTEUS)
Trial name or title PROTEUS study
Methods Prospective, randomised, multicentre, open-label, phase II-III study
Participants People with high-risk proliferative diabetic retinopathy. Number: 94
Interventions Intravitreal injection ranibizumab 0.5 mg plus PRP (group 1) vs. PRP alone (group 2)
Group 1: 3 x intravitreal injections of ranibizumab combined with standard PRP (mean 2 (standard deviation
1) weeks after injection), at month 0, month 1 and month 2 that can be repeated after month 3, with always
at least a 1-month interval between injections
Group 2: PRP between month 0 and month 2, with 1 mandatory laser session in month 0 and more laser
sessions as needed until month 2 to complete the PRP treatment
After completing the PRP treatment, PRP sessions can be repeated from month 3 to month 11
Outcomes Primary:
1. Regression of neovascularisation at 12-month treatment
Secondary:
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NCT01941329 (PROTEUS) (Continued)
1. Changes in BCVA at 12-month treatment
2. Time to complete neovascularisation regression at 12-month treatment
3. Recurrence of neovascularisation at 12-month treatment
4. Macular retinal thickness at 12-month treatment
5. Need of treatment for diabetic macular oedema at 12-month treatment
6. Need of vitrectomy due to the occurrence of vitreous haemorrhage, tractional retinal detachment or
other complications of diabetic retinopathy at 12-month treatment
7. Adverse events related to the treatments at 12-month treatment
Starting date April 2014
Contact information José Cunha-Vaz, MD, PhD; mail: 4c@aibili.pt
Notes NCT01941329
NCT01976923 (PACORES)
Trial name or title PACORES study
Methods Prospective, randomised, active-controlled study
Participants Participants with tractional retinal detachment secondary to proliferative diabetic retinopathy and indication
for vitrectomy. Number: 374
Interventions Intravitreal bevacizumab 1.25 mg/0.05 mL versus small-gauge pars plana vitrectomy
Outcomes Primary:
1. Intraoperative bleeding at 12 months
2. Total surgical time at 12 months
3. Postoperative vitreous haemorrhage at 12 months
4. Visual acuity change at 12 months
Secondary:
1. Number of endodiathermy applications at 12 months
2. Intraoperative breaks at 12 months
3. Change in central macular thickness at 12 months
4. Proportion of eyes gaining at least 15 letters of BCVA at 12 months
Starting date November 2013
Contact information J. Fernando Arevalo, MD, FACS; mail: arevalojf@jhmi.edu
Igor Kozak, MD; mail: ikozak@kkesh.med.sa
Notes NCT01976923
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NCT01988246
Trial name or title PROMISE
Methods Prospective, randomised, controlled, single-masked (participant) study
Participants Prevention of macular oedema in participants with diabetic retinopathy undergoing cataract surgery
Interventions Aflibercept 2 mg intravitreal injection (0.05 mL or 50 µL) administered at time of surgery (post cataract
excision) versus sham injection
Outcomes Primary:
1. Safety and efficacy at day 90
2. Incidence and severity of ocular and non-ocular adverse events and serious adverse events between
treatment arms
Secondary:
1. Visual acuity at day 90
2. Change from baseline in BCVA score at day 90 as measured by ETDRS
3. Macular oedema at day 90
4. Macular oedema as measured by spectral domain ocular coherence tomography at day 90
Starting date December 2013
Contact information Rishi Singh, M.D.; mail: singhr@ccf.org
Gail Kolin, BSN RN; mail: koling@ccf.org
Notes There will be participants with non-proliferative diabetic retinopathy
BCVA: best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; PRP: panretinal photocoagulation; VEGF:
vascular endothelial growth factor.
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation
(PRP) versus PRP alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Visual acuity 5 373 Mean Difference (IV, Random, 95% CI) -0.07 [-0.12, -0.02]
1.1 Pegaptanib 1 16 Mean Difference (IV, Random, 95% CI) -0.06 [-0.22, 0.10]
1.2 Bevacizumab 2 80 Mean Difference (IV, Random, 95% CI) -0.01 [-0.11, 0.09]
1.3 Ranibizumab 2 277 Mean Difference (IV, Random, 95% CI) -0.10 [-0.16, -0.03]
2 Regression of proliferative
diabetic retinopathy
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Presence of vitreous or pre-retinal
haemorrhage
3 342 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.16, 0.65]
3.1 Bevacizumab 1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.92]
3.2 Pegaptanib 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.70]
3.3 Ranibizumab versus
control
1 261 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.18, 0.81]
4 Adverse effects 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Neovascular glaucoma 1 261 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.07, 17.21]
4.2 Retinal detachment 1 261 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.44, 2.25]
4.3 Cataract 1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.63]
4.4 Raised intraocular pressure 2 322 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.42, 1.36]
4.5 Cerebrovascular accident 2 322 Risk Ratio (M-H, Fixed, 95% CI) 3.26 [0.13, 79.34]
4.6 Endophalmitis 1 261 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.82]
4.7 Arterial hypertension 1 261 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.12, 1.76]
Comparison 2. Bevacizumab with vitrectomy compared with vitrectomy alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Loss of 3 or more lines of
ETDRS visual acuity
3 94 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.08, 3.14]
2 Gain of 3 or more lines of
ETDRS visual acuity
3 94 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.20, 2.17]
3 Visual acuity 6 335 Mean Difference (IV, Random, 95% CI) -0.24 [-0.50, 0.01]
4 Presence of vitreous or pre-retinal
haemorrhage
7 393 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.18, 0.52]
5 Adverse effects 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Neovascular glaucoma 1 107 Risk Ratio (M-H, Random, 95% CI) 2.33 [0.28, 19.17]
5.2 Retinal detachment 3 182 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.11, 2.86]
5.3 Cataract 2 137 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.38, 1.23]
5.4 Raised intraocular pressure 1 68 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.47]
5.5 Myocardial infarction 2 175 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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5.6 Cerebrovascular accident 2 175 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.7 Arterial hypertension 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal
photocoagulation (PRP) versus PRP alone, Outcome 1 Visual acuity.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone
Outcome: 1 Visual acuity
Study or subgroup Anti-VEGF PRP
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR]N Mean(SD)[logMAR] IV,Random,95% CI IV,Random,95% CI
1 Pegaptanib
Gonz lez 2009 (1) 8 0.065 (0.195) 8 0.13 (0.118) 9.9 % -0.06 [ -0.22, 0.10 ]
Subtotal (95% CI) 8 8 9.9 % -0.06 [ -0.22, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
2 Bevacizumab
Cho 2010 (2) 31 0.28 (0.28) 30 0.29 (0.21) 16.0 % -0.01 [ -0.13, 0.11 ]
Ergur 2009 (3) 9 0.37 (0.18) 10 0.38 (0.22) 7.6 % -0.01 [ -0.19, 0.17 ]
Subtotal (95% CI) 40 40 23.6 % -0.01 [ -0.11, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
3 Ranibizumab
DRCR.Net 2013 (4) 119 0.56 (0.54) 129 0.72 (0.58) 12.7 % -0.16 [ -0.30, -0.02 ]
Ramos Filho 2011 (5) 15 0 (0.07) 14 0.08 (0.11) 53.8 % -0.08 [ -0.15, -0.01 ]
Subtotal (95% CI) 134 143 66.5 % -0.10 [ -0.16, -0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 3.01 (P = 0.0026)
Total (95% CI) 182 191 100.0 % -0.07 [ -0.12, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.02, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 1.99, df = 2 (P = 0.37), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours anti-VEGF Favours PRP
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(1) Pegaptanib alone compared with PRP alone, change in visual acuity, follow-up 9 months
(2) Bevacizumab and PRP compared with PRP alone, follow-up 3 months
(3) Bevacizumab and PRP compared with PRP alone, follow-up 6 months
(4) Ranibizumab and PRP compared with PRP alone, follow-up 4 months
(5) Ranibizumab and PRP compared with PRP alone, change in visual acuity, follow-up 12 months
Analysis 1.2. Comparison 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal
photocoagulation (PRP) versus PRP alone, Outcome 2 Regression of proliferative diabetic retinopathy.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone
Outcome: 2 Regression of proliferative diabetic retinopathy
Study or subgroup Anti-VEGF PRP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ergur 2009 (1) 9 4.15 (2.26) 10 12.28 (3.85) -8.13 [ -10.94, -5.32 ]
Ramos Filho 2011 (2) 11 6 (3.65) 9 7 (5.7) -1.00 [ -5.30, 3.30 ]
-100 -50 0 50 100
Favours anti-VEGF Favours PRP
(1) Bevacizumab and PRP compared to PRP alone, follow-up 6 months
(2) Ranibizumab and PRP compared to PRP alone, change in area of fluorescein leakage, follow-up 12 months
63Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal
photocoagulation (PRP) versus PRP alone, Outcome 3 Presence of vitreous or pre-retinal haemorrhage.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone
Outcome: 3 Presence of vitreous or pre-retinal haemorrhage
Study or subgroup Anti-VEGF PRP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bevacizumab
Cho 2010 (1) 0/31 4/30 15.7 % 0.11 [ 0.01, 1.92 ]
Subtotal (95% CI) 31 30 15.7 % 0.11 [ 0.01, 1.92 ]
Total events: 0 (Anti-VEGF), 4 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 Pegaptanib
Gonz lez 2009 (2) 0/10 2/10 8.6 % 0.20 [ 0.01, 3.70 ]
Subtotal (95% CI) 10 10 8.6 % 0.20 [ 0.01, 3.70 ]
Total events: 0 (Anti-VEGF), 2 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 Ranibizumab versus control
DRCR.Net 2013 (3) 8/125 23/136 75.7 % 0.38 [ 0.18, 0.81 ]
Subtotal (95% CI) 125 136 75.7 % 0.38 [ 0.18, 0.81 ]
Total events: 8 (Anti-VEGF), 23 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 166 176 100.0 % 0.32 [ 0.16, 0.65 ]
Total events: 8 (Anti-VEGF), 29 (PRP)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0017)
Test for subgroup differences: Chi2 = 0.81, df = 2 (P = 0.67), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours anti-VEGF Favours PRP
(1) Bevacizumab and PRP compared to PRP alone, follow-up 3 months
(2) Pegaptanib alone compared to PRP alone, follow-up 9 months
(3) Ranibizumab and PRP compared to saline and PRP, follow-up 4 months
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Analysis 1.4. Comparison 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal
photocoagulation (PRP) versus PRP alone, Outcome 4 Adverse effects.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 1 Anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone
Outcome: 4 Adverse effects
Study or subgroup Anti-VEGF PRP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Neovascular glaucoma
DRCR.Net 2013 1/125 1/136 100.0 % 1.09 [ 0.07, 17.21 ]
Subtotal (95% CI) 125 136 100.0 % 1.09 [ 0.07, 17.21 ]
Total events: 1 (Anti-VEGF), 1 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Retinal detachment
DRCR.Net 2013 10/125 11/136 100.0 % 0.99 [ 0.44, 2.25 ]
Subtotal (95% CI) 125 136 100.0 % 0.99 [ 0.44, 2.25 ]
Total events: 10 (Anti-VEGF), 11 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
3 Cataract
Cho 2010 0/31 1/30 100.0 % 0.32 [ 0.01, 7.63 ]
Subtotal (95% CI) 31 30 100.0 % 0.32 [ 0.01, 7.63 ]
Total events: 0 (Anti-VEGF), 1 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
4 Raised intraocular pressure
Cho 2010 0/31 4/30 20.1 % 0.11 [ 0.01, 1.92 ]
DRCR.Net 2013 16/125 19/136 79.9 % 0.92 [ 0.49, 1.70 ]
Subtotal (95% CI) 156 166 100.0 % 0.75 [ 0.42, 1.36 ]
Total events: 16 (Anti-VEGF), 23 (PRP)
Heterogeneity: Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.94 (P = 0.35)
5 Cerebrovascular accident
Cho 2010 0/31 0/30 Not estimable
DRCR.Net 2013 1/125 0/136 100.0 % 3.26 [ 0.13, 79.34 ]
Subtotal (95% CI) 156 166 100.0 % 3.26 [ 0.13, 79.34 ]
Total events: 1 (Anti-VEGF), 0 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.01 0.1 1 10 100
Favours antiVEGF Favours PRP
(Continued . . . )
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(. . . Continued)
Study or subgroup Anti-VEGF PRP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Endophalmitis
DRCR.Net 2013 0/125 1/136 100.0 % 0.36 [ 0.01, 8.82 ]
Subtotal (95% CI) 125 136 100.0 % 0.36 [ 0.01, 8.82 ]
Total events: 0 (Anti-VEGF), 1 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
7 Arterial hypertension
DRCR.Net 2013 3/125 7/136 100.0 % 0.47 [ 0.12, 1.76 ]
Subtotal (95% CI) 125 136 100.0 % 0.47 [ 0.12, 1.76 ]
Total events: 3 (Anti-VEGF), 7 (PRP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
0.01 0.1 1 10 100
Favours antiVEGF Favours PRP
Analysis 2.1. Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 1
Loss of 3 or more lines of ETDRS visual acuity.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 2 Bevacizumab with vitrectomy compared with vitrectomy alone
Outcome: 1 Loss of 3 or more lines of ETDRS visual acuity
Study or subgroup
Bevacizumab
+ vitrectomy Vitrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Batarny 2008 (1) 0/15 1/15 45.8 % 0.33 [ 0.01, 7.58 ]
Sohn 2012 (2) 0/5 0/5 Not estimable
Zaman 2013 (3) 1/24 2/30 54.2 % 0.63 [ 0.06, 6.49 ]
Total (95% CI) 44 50 100.0 % 0.49 [ 0.08, 3.14 ]
Total events: 1 (Bevacizumab + vitrectomy), 3 (Vitrectomy)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours bevacizumab Favours no bevacizumab
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(1) Bevacizumab given 5-7 days before vitrectomy, reported ”deterioration” in vision, follow-up 12 months
(2) Bevacizumab given 3-7 days before vitrectomy, control group received sham injection, reported ”loss of 3 or more lines”, follow-up 3 months
(3) Bevacizumab given 1 week before vitrectomy, reported ”deterioration” in vision, follow-up 6 months
Analysis 2.2. Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 2
Gain of 3 or more lines of ETDRS visual acuity.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 2 Bevacizumab with vitrectomy compared with vitrectomy alone
Outcome: 2 Gain of 3 or more lines of ETDRS visual acuity
Study or subgroup
Bevacizumab
+ vitrectomy Vitrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Batarny 2008 (1) 13/15 12/15 50.7 % 1.08 [ 0.79, 1.49 ]
Sohn 2012 (2) 3/5 1/5 4.2 % 3.00 [ 0.45, 19.93 ]
Zaman 2013 (3) 20/24 12/30 45.1 % 2.08 [ 1.30, 3.34 ]
Total (95% CI) 44 50 100.0 % 1.62 [ 1.20, 2.17 ]
Total events: 36 (Bevacizumab + vitrectomy), 25 (Vitrectomy)
Heterogeneity: Chi2 = 7.44, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 3.16 (P = 0.0016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no bevacizumab Favours bevacizumab
(1) Bevacizumab given 5-7 days before vitrectomy, reported ”improvement” in vision, follow-up 12 months
(2) Bevacizumab given 3-7 days before vitrectomy, control group received sham injection, reported ”gain of 3 or more lines”, follow-up 3 months
(3) Bevacizumab given 1 week before vitrectomy, reported ”improvement” in vision, follow-up 6 months
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Analysis 2.3. Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 3
Visual acuity.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 2 Bevacizumab with vitrectomy compared with vitrectomy alone
Outcome: 3 Visual acuity
Study or subgroup
Bevacizumab
+ vitrectomy Vitrectomy
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Random,95% CI IV,Random,95% CI
Ahmadieh 2009 (1) 35 0.91 (0.65) 33 1.46 (0.65) 19.8 % -0.55 [ -0.86, -0.24 ]
Ahn 2011 (2) 73 0.65 (0.52) 34 0.51 (0.56) 23.1 % 0.14 [ -0.08, 0.36 ]
Di Lauro 2010 (3) 48 0.84 (1.1) 24 1.2 (1.4) 10.1 % -0.36 [ -1.00, 0.28 ]
El-Batarny 2008 (4) 15 0.75 (0.68) 15 0.91 (0.67) 13.9 % -0.16 [ -0.64, 0.32 ]
Modarres 2009 (5) 22 1.1 (0.4) 18 1.4 (0.3) 23.3 % -0.30 [ -0.52, -0.08 ]
Sohn 2012 (6) 9 0.97 (0.7) 9 1.35 (0.71) 9.9 % -0.38 [ -1.03, 0.27 ]
Total (95% CI) 202 133 100.0 % -0.24 [ -0.50, 0.01 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 15.23, df = 5 (P = 0.01); I2 =67%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours bevacizumab Favours no bevacizumab
(1) Bevacizumab given 1 week before vitrectomy, control group received sham injection, follow-up 1 month
(2) Bevacizumab given 1-14 days before or during vitrectomy, follow-up 6 months
(3) Bevacizumab given 1-3 weeks before vitrectomy, control group received sham injection, follow-up 6 months
(4) Bevacizumab given 5-7 days before vitrectomy, follow-up 12 months
(5) Bevacizumab given 3-5 days before vitrectomy, follow-up 7 months
(6) Bevacizumab given 3-7 days before vitrectomy, control group received sham injection, follow-up 3 months
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Analysis 2.4. Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 4
Presence of vitreous or pre-retinal haemorrhage.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 2 Bevacizumab with vitrectomy compared with vitrectomy alone
Outcome: 4 Presence of vitreous or pre-retinal haemorrhage
Study or subgroup
Bevacizumab
+ vitrectomy Vitrectomy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ahmadieh 2009 (1) 9/35 26/33 25.0 % 0.33 [ 0.18, 0.59 ]
Ahn 2011 (2) 24/73 18/34 28.5 % 0.62 [ 0.39, 0.98 ]
Di Lauro 2010 (3) 4/48 8/24 14.2 % 0.25 [ 0.08, 0.75 ]
El-Batarny 2008 (4) 0/15 4/15 3.2 % 0.11 [ 0.01, 1.90 ]
Modarres 2009 (5) 0/22 7/18 3.3 % 0.06 [ 0.00, 0.90 ]
Rizzo 2008 (6) 2/11 9/11 11.6 % 0.22 [ 0.06, 0.80 ]
Zaman 2013 (7) 3/24 20/30 14.3 % 0.19 [ 0.06, 0.56 ]
Total (95% CI) 228 165 100.0 % 0.30 [ 0.18, 0.52 ]
Total events: 42 (Bevacizumab + vitrectomy), 92 (Vitrectomy)
Heterogeneity: Tau2 = 0.20; Chi2 = 11.40, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours bevacizumab Favours no bevacizumab
(1) Bevacizumab given 1 week before vitrectomy, control group received sham injection, follow-up 1 month
(2) Bevacizumab given 1-14 days before or during vitrectomy, follow-up 6 months
(3) Bevacizumab given 1-3 weeks before vitrectomy, control group received sham injection, follow-up 6 months
(4) Bevacizumab given 5-7 days before vitrectomy, follow-up 12 months
(5) Bevacizumab given 3-5 days before vitrectomy, follow-up 7 months
(6) Bevacizumab given 5-7 days before vitrectomy, follow-up 6 months
(7) Bevacizumab given 1 week before vitrectomy, follow-up 6 months
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Analysis 2.5. Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 5
Adverse effects.
Review: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Comparison: 2 Bevacizumab with vitrectomy compared with vitrectomy alone
Outcome: 5 Adverse effects
Study or subgroup Anti-VEGF + surgery Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Neovascular glaucoma
Ahn 2011 5/73 1/34 100.0 % 2.33 [ 0.28, 19.17 ]
Subtotal (95% CI) 73 34 100.0 % 2.33 [ 0.28, 19.17 ]
Total events: 5 (Anti-VEGF + surgery), 1 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 Retinal detachment
Ahn 2011 0/73 1/34 26.5 % 0.16 [ 0.01, 3.77 ]
Modarres 2009 1/22 1/18 36.6 % 0.82 [ 0.05, 12.19 ]
Farahvash 2011 1/18 1/17 36.9 % 0.94 [ 0.06, 13.93 ]
Subtotal (95% CI) 113 69 100.0 % 0.56 [ 0.11, 2.86 ]
Total events: 2 (Anti-VEGF + surgery), 3 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
3 Cataract
Ahn 2011 5/73 5/34 25.3 % 0.47 [ 0.14, 1.50 ]
El-Batarny 2008 7/15 9/15 74.7 % 0.78 [ 0.39, 1.54 ]
Subtotal (95% CI) 88 49 100.0 % 0.68 [ 0.38, 1.23 ]
Total events: 12 (Anti-VEGF + surgery), 14 (Surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
4 Raised intraocular pressure
Ahmadieh 2009 0/35 1/33 100.0 % 0.31 [ 0.01, 7.47 ]
Subtotal (95% CI) 35 33 100.0 % 0.31 [ 0.01, 7.47 ]
Total events: 0 (Anti-VEGF + surgery), 1 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
5 Myocardial infarction
Ahmadieh 2009 0/35 0/33 Not estimable
Ahn 2011 0/73 0/34 Not estimable
Subtotal (95% CI) 108 67 Not estimable
0.01 0.1 1 10 100
Favours anti-VEGF+surgery Favours surgery
(Continued . . . )
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(. . . Continued)
Study or subgroup Anti-VEGF + surgery Surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Anti-VEGF + surgery), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Cerebrovascular accident
Ahn 2011 0/73 0/34 Not estimable
Ahmadieh 2009 0/35 0/33 Not estimable
Subtotal (95% CI) 108 67 Not estimable
Total events: 0 (Anti-VEGF + surgery), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Arterial hypertension
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Anti-VEGF + surgery), 0 (Surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.57, df = 3 (P = 0.67), I2 =0.0%
0.01 0.1 1 10 100
Favours anti-VEGF+surgery Favours surgery
A D D I T I O N A L T A B L E S
Table 1. ETDRS classification of diabetic retinopathy
Mild Presence of at least 1 microaneurysm
Moderate Haemorrhages or microaneurysms (or both) more than standard photo 2A, presence of soft exudates, venous
beading, IRMA definitively present
Severe Haemorrhages or microaneurysms (or both) more than standard photo 2A in all 4 quadrants, or venous beading
in ≥ 2 quadrants, or IRMA more than standard photo 8A in at least 1 quadrant
Very severe Any ≥ 2 of the changes seen in severe NPDR
Early PDR Presence of new vessels
High-risk PDR Any of the following: NVD more than one-third to one-quarter disc diameter, NVD less than one-third to one-
quarter disc diameter with vitreous or pre-retinal haemorrhage, new vessels elsewhere with vitreous or pre-retinal
haemorrhage
ETDRS: Early Treatment Diabetic Retinopathy Study; IRMA: intraretinal microaneurysm; NPDR: non-proliferative diabetic retinopa-
thy; NVD: new vessels at optic disc; PDR: proliferative diabetic retinopathy.
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Table 2. ICDRDS scale
Non-apparent retinopathy No abnormalities
Mild NPDR Microaneurysms only
Moderate NPDR More than just microaneurysms but less than severe NPDR
Severe NPDR Any of the following: > 20 intraretinal haemorrhages in each of 4 quadrants; definite venous
beading in 2 quadrants; prominent intraretinal microvascular abnormalities in 1 quadrant and no
signs of proliferative retinopathy
Proliferative diabetic retinopathy ≥ 1 of the following: neovascularisation, vitreous or pre-retinal haemorrhage
ICDRDS: International Clinical Diabetic Retinopathy Disease Severity scale; NPDR: non-proliferative diabetic retinopathy.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#2 diabet* near/3 retinopath*
#3 proliferat* near/3 retinopath*
#4 (retinopath* or retinal or intraocular or intravitreal or glaucoma) near/2 (neovascular*)
#5 new blood vessel
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Angiogenesis Inhibitors] explode all trees
#8 MeSH descriptor: [Angiogenesis Inducing Agents] explode all trees
#9 MeSH descriptor: [Endothelial Growth Factors] explode all trees
#10 anti near/2 VEGF*
#11 endothelial near/2 growth near/2 factor*
#12 anti near/1 angiogen*
#13 macugen* or pegaptanib* or lucentis* or rhufab* or ranibizumab* or bevacizumab* or avastin or aflibercept*
#14 VEGF TRAP*
#15 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 #6 and #15
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Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp diabetic retinopathy/
14. (diabet$ adj3 retinopath$).tw.
15. (proliferat$ adj3 retinopath$).tw.
16. ((retinopath$ or retinal or intraocular or intravitreal or glaucoma) adj2 neovascular$).tw.
17. new blood vessel$.tw.
18. or/13-17
19. exp angiogenesis inhibitors/
20. exp angiogenesis inducing agents/
21. exp endothelial growth factors/
22. (anti adj2 VEGF$).tw.
23. (endothelial adj2 growth adj2 factor$).tw.
24. (anti adj1 angiogen$).tw.
25. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin or aflibercept$).tw.
26. VEGF TRAP$.tw.
27. or/19-25
28. 18 and 27
29. 12 and 28
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
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19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp diabetic retinopathy/
34. (diabet$ adj3 retinopath$).tw.
35. (proliferat$ adj3 retinopath$).tw.
36. ((retinopath$ or retinal or intraocular or intravitreal or glaucoma) adj2 neovascular$).tw.
37. new blood vessel$.tw.
38. or/33-37
39. angiogenesis/
40. angiogenesis inhibitors/
41. angiogenesis factor/
42. monoclonal antibody/
43. exp endothelial cell growth factor/
44. vasculotropin/
45. (anti adj2 VEGF$).tw.
46. (endothelial adj2 growth adj2 factor$).tw.
47. (anti adj1 angiogen$).tw.
48. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin or aflibercept$).tw.
49. VEGF TRAP$.tw.
50. or/39-49
51. 38 and 50
52. 32 and 51
Appendix 4. metaRegister of Controlled Trials search strategy
(macugen or pegaptanib or lucentis or rhufab or ranibizumab or bevacizumab or avastin or aflibercept) and (diabetic retinopathy)
Appendix 5. ClinicalTrials.gov search strategy
(Macugen OR Pegaptanib OR Lucentis OR Rhufab OR Ranibizumab OR Bevacizumab OR Avastin OR Aflibercept) AND (Diabetic
Retinopathy)
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Appendix 6. ICTRP search strategy
Diabetic Retinopathy = Condition ANDMacugen OR Pegaptanib OR Lucentis OR Rhufab OR Ranibizumab OR Bevacizumab OR
Avastin OR Aflibercept = Intervention
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following amendments to the protocol (Martinez-Zapata 2010).
1. In the protocol, we had not considered that anti-VEGFs would be used in different patient groups with PDR (i.e. people eligible
for laser treatment, people eligible for vitrectomy and people undergoing cataract surgery. We felt that clinically it did not make sense
to combine these different patient groups and so have presented the results separately.
2. In the protocol, the primary outcome was regression of proliferative retinopathy and visual acuity was a secondary outcome. On
reflection, we felt this was the wrong emphasis and considered that the effect on visual acuity was more relevant for the person than
checking if anti-VEGFs could produce regression of new vessels. We have changed visual acuity to the primary outcome and
considered regression of proliferative retinopathy as a secondary outcome.
3. In the protocol, we planned to exclude from the analysis studies where the fellow eye was used as a control (i.e. the within-person
studies). However, some studies had a parallel group design but included a low percentage of participants with the fellow eye used as a
control. We included these studies in the analysis.
4. We did not calculate the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat
for an additional harmful outcome (NNTH) due to the low quality of the evidence.
5. In the protocol, we planned to do a sensitivity analysis by intention-to-treat considering the “worst-case scenario”. In the event,
we did not do this, partly due to the characteristics of the majority of studies and partly because, on reflection, we felt that this
analysis was too extreme and unlikely to be informative.
6. We planned to do a sensitivity analysis excluding unpublished studies but did not have any data on unpublished studies to do
this.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal, Humanized [therapeutic use]; Aptamers, Nucleotide [therapeutic use]; Bevacizumab; Diabetic Retinopathy
[∗drug therapy; surgery]; Light Coagulation [methods]; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial
Growth Factor A [∗therapeutic use]; Visual Acuity [drug effects]; Vitrectomy; Vitreoretinopathy, Proliferative [∗drug therapy; surgery]
MeSH check words
Female; Humans; Male
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